BETHESDA, Md., Oct. 08, 2026 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small-molecule therapies, today announced it will participate in the upcoming 2026 Maxim Growth Summit, taking place from October 12th to 14th at The Hard Rock Hotel New York, in New York City.

Gain Therapeutics will be meeting with institutional investors in one-on-one meeting sessions and engaging with senior Maxim research analysts throughout the event.

If you are interested in meeting with Gain management, please contact your Maxim sales representative to schedule.

About the Maxim Growth Summit

This prestigious event brings together industry leaders, innovators, and premier institutions to explore the latest trends and advancements across several industries.

Keynote speakers include Marcus Lemonis (co-owner of Camping World and executive chairman of Neighborhood Intelligence) and Eric Adams (former mayor of New York City). The conference will also feature roundtable discussions with CEOs from small- and mid-cap companies, moderated by Maxim research analysts. Roundtable discussions will cover a range of sectors, including biotechnology, artificial intelligence, quantum technology, digital assets, energy and mining, drones, and more.

This year, portions of the event will also be streamed online at https://digital.maximgrp.com/.

For more information and a complete agenda of the Maxim Growth Summit, please visit www.maximgrp.com/2026-growth-summit.

About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next-generation allosteric therapies. Gain’s lead drug candidate, rexaceract is currently being evaluated for the treatment of PD with or without a GBA1 mutation in a Phase 1b clinical trial. Rexaceract has further potential in Gaucher’s disease, dementia with Lewy bodies, and Alzheimer’s disease. Gain has multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumors.

Gain’s unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced Magellan™ platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology.

Forward-Looking Statements
This release contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions. These forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, statements regarding: the development of the Company’s current or future product candidates; expectations regarding the timing of patient enrollment and the completion and timing of results from a Phase 1b clinical study for rexaceract, including any extension studies; the timing of any submissions to the FDA or other regulatory bodies and agencies; the timing of the commencement of the Phase 2 clinical study for rexaceract; the Company’s ability to enroll patients in its planned Phase 2 clinical study for rexaceract; the Company’s ability to replicate positive results from earlier preclinical studies or clinical trials in current or future clinical trials; the Company’s business development activities, strategic collaborations, licensing opportunities and financing activities; the advancement, prioritization and timing of the Company’s pipeline programs, including GT-04686; and the potential therapeutic and clinical benefits of the Company’s product candidates. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business in general, please refer to the Company’s Form 10-K for the year ended December 31, 2025, and other filings made with the SEC. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether because of new information, future events or otherwise.

Investors:
Gain Therapeutics, Inc. 
Apaar Jammu 
Director, Investor Relations and Public Relations
ajammu@gaintherapeutics.com

LifeSci Advisors LLC
Chuck Padala
Managing Director
chuck@lifesciadvisors.com

Media:
Russo Partners LLC
Nic Johnson and Elio Ambrosio
nic.johnson@russopartnersllc.com
elio.ambrosio@russopartnersllc.com
(760) 846-9256

First-Quarter Results Reinforce Tilray’s Progress Converting Global Scale, Disciplined Execution and Category Leadership into Higher Revenue, Expanded Gross Profit and Continued Momentum

Record First-Quarter Net Revenue of $257 Million, Up 23% Year-Over-Year, with Gross Margin Expanding by ~300 bps to 30%

International Business Accelerates as EMEA Revenue Increases 71%, Growth Led by Medical Cannabis, Beverage and Pharmaceutical Distribution

Tilray’s Global Beverage Business Delivers $101 Million in Revenue, Expands Gross Margin to 41% and BrewDog Achieves Profitability in Q1

Reduced Outstanding Debt by $42 Million Fiscal Year-to-Date and Ended the Q1 with a Net Cash1 Position, Strengthening Financial Flexibility and the Balance Sheet

Tilray Reaffirms Fiscal 2027 Adjusted EBITDA3 Guidance of $68 Million to $75 Million

NEW YORK and LONDON and LEAMINGTON, Ontario, Oct. 08, 2026 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray”, “our”, “we” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company with leading positions across cannabis, beverage, hospitality and wellness, today reported financial results for its first fiscal quarter ended August 31, 2026. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.

Irwin D. Simon, Chairman and Chief Executive Officer, Tilray Brands, stated: “Tilray’s record first-quarter revenue and gross profit demonstrate the power of the diversified platform we have built and the momentum we are creating across cannabis, beverage, hospitality, wellness and pharmaceutical distribution. We are no longer dependent on a single market or regulatory catalyst. We have multiple engines of growth, a scaled international footprint and the ability to convert scale into stronger margins, greater efficiency and sustainable, profitable growth.”

Mr. Simon continued, “Our global platform is translating into leadership positions across our core categories. In cannabis, Tilray is a leading cannabis producer, with more than 6 million square feet of cultivation capacity across Canada, Portugal and Germany, and a leading low-cost production base in the world’s largest legally regulated markets, supported by one of the largest EU-GMP certified footprints in the world. In beer, the world’s largest consumed alcoholic beverage category, we are the #4 craft brewer in the U.S. and #1 in the U.K., and we are very proud that Carlsberg has partnered with Tilray to begin producing and selling its iconic brands in the U.S. market starting January 1, 2027. Across beverage and wellness, we are accelerating innovation and staying closer to consumers. These leadership positions reflect the work we have done to integrate our businesses, sharpen operations and build a more focused, profitable company. Tilray is building a category-defining global platform for the next generation of wellness, healthcare and consumer products, with the brands, infrastructure and scale to lead as these markets evolve.”

The quarter’s performance reflects Tilray’s focus on building durable growth across multiple categories, strengthening profitability and maintaining a disciplined balance sheet while investing behind the long-term opportunities we believe will define the future of cannabis, beverage, wellness and healthcare.

Financial Highlights
All comparisons made to the prior year period

  • Net revenue increased 23% year-over-year to $257.1 million in the first quarter, compared to $209.5 million.
  • Gross profit increased 35% year-over-year to $77.5 million in the first quarter, compared to $57.5 million, while gross margin expanded to 30% from 27%.
  • Cannabis net revenue was $56.1 million in the first quarter compared to $64.5 million.
    • Cannabis gross profit was $22.0 million in the first quarter compared to $23.3 million.
    • Cannabis gross margin expanded to 39% in the first quarter compared to 36%.
  • Beverage net revenue increased 82% year-over-year to $101.5 million in the first quarter, compared to $55.7 million, reflecting the acquisition of BrewDog.
    • Beverage gross profit increased to $42.0 million in the first quarter compared to $21.3 million.
    • Beverage gross margin expanded to 41% in the first quarter compared to 38%.
  • Distribution net revenue increased 14% to $84.3 million in the first quarter compared to $74.0 million.
    • Distribution gross profit increased $9.1 million in the first quarter compared to $8.0 million.
    • Distribution gross margin was 11% in the first quarter and was unchanged.
  • Wellness net revenue was $15.3 million, consistent with the previous year period.
    • Wellness gross profit was $4.4 million in the first quarter compared to $4.9 million.
    • Wellness gross margin was 29% in the first quarter compared to 32%.
  • Driven predominantly by non-cash charges, net loss was $40.0 million in the first quarter and net loss per share was $0.32. Adjusted net loss2  was $3.0 million in the first quarter and adjusted net loss per share or adjusted EPS2 was $0.02.
  • Adjusted EBITDA3 was $9.2 million in the first quarter compared to $10.2 million; burdened by approximately $1.7 million of global fuel surcharges in this quarter.

Balance Sheet Update: Tilray’s balance sheet remains strong, supported by cash, restricted cash and marketable securities4 of $221.4 million at the end of the first quarter. This position gives the Company financial flexibility to invest behind strategic growth opportunities, support integration priorities and maintain disciplined capital allocation. Fiscal year to date, Tilray also reduced total outstanding debt by $42 million.

Fiscal Year 2027 Guidance
For its fiscal year ending May 31, 2027, the Company reaffirms its expectation to achieve adjusted EBITDA3 of $68 million to $75 million, representing double-digit growth as compared to fiscal year 2026. Historically, due to the seasonality of our business, financial results are typically more weighted toward the second half of the fiscal year, with results strengthening significantly in the fourth quarter.

Management’s guidance for adjusted EBITDA3 is provided on a non-GAAP basis and excludes stock-based compensation; change in fair value of contingent consideration; purchase price accounting step-up; impairments of intangible assets and goodwill; other than temporary change in fair value of convertible notes receivable; litigation costs; integration and restructuring costs; transaction-related costs; and other non-operating income (expenses) and non-recurring items that may be incurred during the Company’s fiscal year 2027, which the Company will continue to identify as it reports its future financial results.

The Company cannot reconcile its expected adjusted EBITDA3 to net income under “Fiscal Year 2027 Guidance” without unreasonable effort because certain items that impact net income and other reconciling metrics are out of the Company’s control and/or cannot be reasonably predicted at this time.

____________________________________________________________________________________________________

(1) Net (debt) cash is a non-GAAP financial measure. See “Use of Non-GAAP Measures” below for additional discussion regarding these non-GAAP measures and for a reconciliation of such Non-GAAP Measures to our most comparable GAAP measure.
(2) Adjusted net income (loss) and adjusted net income (loss) per share/Adjusted EPS are a non-GAAP financial measure. See “Use of Non-GAAP Measures” below for additional discussion regarding these non-GAAP measures and for a reconciliation of such Non-GAAP Measures to our most comparable GAAP measure.
(3) Adjusted EBITDA is a non-GAAP financial measure. See “Use of Non-GAAP Measures” below for additional discussion regarding these non-GAAP measures and for a reconciliation of such Non-GAAP Measures to our most comparable GAAP measure.
(4) Cash, restricted cash and Marketable Securities is a non-GAAP financial measure. See “Use of Non-GAAP Measures” below for additional discussion regarding these non-GAAP measures and for a reconciliation of such Non-GAAP Measures to our most comparable GAAP measure.

Live Audio Webcast
Tilray Brands will host a webcast to discuss these results today at 8:30 AM Eastern Time. Investors may access the live webcast through the Events and Presentations section of Tilray’s Investor Relations website, where a replay will also be available and archived.

About Tilray Brands
Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.

For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms.

Cautionary Statement Concerning Forward-Looking Statements
Certain statements in this press release constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “position,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication.

Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the Company’s ability to become a leading lifestyle consumer packaged goods company; the Company’s ability to become a leading beverage alcohol Company; the Company’s ability to achieve long term profitability; the Company’s ability to achieve operational scale, market share, distribution, profitability and revenue growth in particular business lines and markets; the Company’s ability to successfully achieve revenue growth, margin and profitability improvements, production and supply chain efficiencies, synergies and cost savings; the Company’s ability to achieve fiscal year 2027 financial guidance, including expected Adjusted EBITDA3 of $68 to $75 million and synergy optimizations; the Company’s expected revenue growth, sales volume, profitability, synergies and accretion related to any of its acquisitions; expected opportunities in the U.S., including upon U.S. federal cannabis legalization or rescheduling and the Company’s ability to leverage its platform in connection therewith; the Company’s ability to successfully leverage artificial intelligence strategies; the Company’s anticipated investments and acquisitions, including in organic and strategic growth, partnership efforts, product offerings and other initiatives; and the Company’s ability to commercialize new and innovative products.

Many factors could cause actual results, performance or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of the Company and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of the Company made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

Use of Non-U.S. GAAP Financial Measures
This press release and the accompanying tables include non-GAAP financial measures, including Adjusted EBITDA3, Adjusted cash operating income (loss), Adjusted net income (loss), Adjusted net income (loss) per share and or (“Adjusted EPS”), free cash flow, adjusted free cash flow, constant currency presentations of revenue, cash, restricted cash and marketable securities, and net (debt) cash. Management believes that the non-GAAP financial measures presented provide useful additional information to investors about current trends in the Company’s operations and are useful for period-over-period comparisons of operations. These non-GAAP financial measures should not be considered in isolation or as a substitute for the comparable GAAP measures, nor should adjusted net income (loss) per share be used as a measure of liquidity. In addition, these non-GAAP measures may not be the same as similar measures provided by other companies due to potential differences in methods of calculation and items being excluded. They should be read only in connection with the Company’s Consolidated Statements of Operations and Cash Flows presented in accordance with GAAP.

Certain forward-looking non-GAAP financial measures included in this press release are not reconciled to the comparable forward-looking GAAP financial measures. The Company is not able to reconcile these forward-looking non-GAAP financial measures to their most directly comparable forward-looking GAAP financial measures without unreasonable efforts because the Company is unable to predict with a reasonable degree of certainty the type and extent of certain items that would be expected to impact GAAP measures but would not impact the non-GAAP measures. Such items may include litigation and related expenses, transaction costs, impairments of intangible assets and goodwill, foreign exchange movements and other items. The unavailable information could have a significant impact on the Company’s GAAP financial results.

The Company believes presenting net sales at constant currency provides useful information to investors because it provides transparency to underlying performance in the Company’s consolidated net sales by excluding the effect that foreign currency exchange rate fluctuations have on period-to-period comparability given the volatility in foreign currency exchange markets. To present this information for historical periods, current period net sales for entities reporting in currencies other than the U.S. dollar are translated into U.S. dollars at the average monthly exchange rates in effect during the corresponding period of the prior fiscal year, rather than at the actual average monthly exchange rate in effect during the current period of the current fiscal year. As a result, the foreign currency impact is equal to the current year results in local currencies multiplied by the change in average foreign currency exchange rate between the current fiscal period and the corresponding period of the prior fiscal year. A reconciliation of prior year revenue to constant currency revenue, the most directly comparable GAAP measure, has been provided in the financial statement tables included above in this press release.

Adjusted EBITDA3 is calculated as net income (loss) before income tax expense (recovery), net; interest expense, net; non-operating income (expense), net; amortization; stock-based compensation; change in fair value of contingent consideration; project 420 optimization costs; litigation costs; restructuring costs, and transaction costs, net. A reconciliation of Adjusted EBITDA3 to net income (loss), the most directly comparable GAAP measure, has been provided in the financial statement tables included below in this press release.

Adjusted cash operating income (loss) is calculated as operating loss, less; amortization; stock-based compensation; and change in fair value of contingent consideration. A reconciliation of adjusted cash operating income (loss) to operating loss, the most directly comparable GAAP measure, has been included below in this press release. Adjusted cash operating income (loss) is not calculated in accordance with GAAP and should not be considered an alternative for GAAP operating income or as a measure of liquidity.

Adjusted net income (loss) is calculated as net loss attributable to stockholders of Tilray Brands, Inc., less; non-operating income (expense), net; amortization; deferred income tax expense (benefits), net; stock-based compensation; Accretion of convertible debt discount; change in fair value of contingent consideration; project 420 optimization costs; litigation costs; restructuring costs and transaction costs, net. A reconciliation of Adjusted net income (loss) to net loss attributable to stockholders of Tilray Brands, Inc., the most directly comparable GAAP measure, has been included below in this press release.

Adjusted net income (loss) per share (and or adjusted EPS) is calculated as adjusted net income (loss) divided by weighted average number of common shares outstanding. A reconciliation of Adjusted net income (loss) per share to net loss attributable to stockholders of Tilray Brands, Inc., the most directly comparable GAAP measure, has been included below in this press release. Adjusted net income (loss) per share is not calculated in accordance with GAAP and should not be considered an alternative for GAAP net income (loss) per share or as a measure of liquidity.

Free cash flow is comprised of two GAAP measures which are net cash flow provided by (used in) operating activities less investments in capital and intangible assets, net. A reconciliation of net cash flow provided by (used in) operating activities to free cash flow, the most directly comparable GAAP measure, has been provided in the financial statement tables included above in this press release. Adjusted free cash flow is comprised of two GAAP measures which are net cash flow provided by (used in) operating activities less investments in capital and intangible assets, net, and the exclusion of growth CAPEX from investments in capital and intangible assets, net, which excludes the amount of capital expenditures that are considered to be associated with growth of future operations rather than to maintain the existing operations of the Company, and excludes cash paid for litigation settlements. A reconciliation of net cash flow provided by (used in) operating activities to adjusted free cash flow, the most directly comparable GAAP measure, has been provided in the financial statement tables included above in this press release.

Cash, restricted cash and marketable securities are comprised of three GAAP measures, cash and cash equivalents and restricted cash added to marketable securities. The Company’s management believes that this presentation provides useful information to management, analysts and investors regarding certain additional financial and business trends relating to its short-term liquidity position by combining these three GAAP metrics.

Net (debt) cash is comprised of GAAP measures and reduces bank indebtedness, current and non-current portions of long-term debt, the principal balance of convertible debt by cash and cash equivalents and marketable securities. The Company believes this metric provides useful information to management, analysts, and investors regarding its liquidity and the Company’s ability to repay all of its debt.

Contacts:
Investor Relations
investors@tilray.com
Pro-TLRY@prosek.com

Media
news@tilray.com

The accompanying excerpts of the interim condensed consolidated financial statements are unaudited and have been prepared in accordance with U.S. GAAP. 

Consolidated Statements of Financial Position      
  August 31,   May 31,
(in thousands of US dollars) 2026   2026
Assets      
Current assets      
Cash and cash equivalents $ 214,960     $ 225,977  
Restricted cash   3,383       3,365  
Marketable securities   3,047       5,289  
Accounts receivable, net   190,617       189,170  
Inventory   328,973       301,192  
Prepaids and other current assets   64,160       64,692  
Assets held for sale   2,449       2,449  
Total current assets   807,589       792,134  
Capital assets   665,923       680,225  
Operating lease, right-of-use assets   42,030       42,318  
Digital assets   720       674  
Intangible assets   42,468       42,779  
Goodwill   752,350       752,350  
Long-term investments   6,365       6,551  
Other assets   10,509       10,981  
Total assets $ 2,327,954     $ 2,328,012  
Liabilities      
Current liabilities      
Bank indebtedness $ 8,688     $ 8,775  
Accounts payable and accrued liabilities   335,415       318,088  
Current portion of lease liabilities   11,902       13,357  
Current portion of long-term debt   15,457       18,160  
Current portion of convertible debentures payable   59,224       —  
Total current liabilities   430,686       358,380  
Long – term liabilities      
Lease liabilities   158,610       158,155  
Long-term debt   118,046       120,425  
Convertible debentures payable   —       79,529  
Deferred tax liabilities, net   9,746       12,256  
Other liabilities   4,192       4,400  
Total liabilities   721,280       733,145  
Stockholders’ equity      
Common stock ($0.0001 par value; 1,416,000,000 common shares authorized; 144,936,074 and 131,683,075 common shares issued and outstanding, respectively)   145       132  
Treasury Stock (1,124,869 and 589,217 treasury shares issued and outstanding, respectively)   —       —  
Preferred shares ($0.0001 par value; 10,000,000 preferred shares authorized; nil and nil preferred shares issued and outstanding, respectively)   —       —  
Additional paid-in capital   6,674,469       6,627,056  
Accumulated other comprehensive loss   (39,492 )     (44,233 )
Accumulated deficit   (5,011,764 )     (4,968,623 )
Total Tilray Brands, Inc. stockholders’ equity   1,623,358       1,614,332  
Non-controlling interests   (16,684 )     (19,465 )
Total stockholders’ equity   1,606,674       1,594,867  
Total liabilities and stockholders’ equity $ 2,327,954     $ 2,328,012  
       

Condensed Consolidated Statements of Net Income (Loss) and Comprehensive Income (Loss)        
  For the three months ended        
  August 31,   August 31,   Change   % Change
(in thousands of U.S. dollars, except for per share data) 2026   2025   2026 vs. 2025
Net revenue $ 257,147     $ 209,501     $ 47,646     23 %
Cost of goods sold   179,638       152,032       27,606     18 %
Gross profit   77,509       57,469       20,040     35 %
Operating expenses:              
General and administrative   57,608       41,053       16,555     40 %
Selling   13,593       12,923       670     5 %
Amortization   6,500       3,929       2,571     65 %
Marketing and promotion   15,736       10,155       5,581     55 %
Research and development   89       41       48     117 %
Change in fair value of contingent consideration   —       (15,000 )     15,000     (100 )%
Litigation costs, net of recoveries   787       1,007       (220 )   (22 )%
Restructuring costs   2,447       869       1,578     182 %
Transaction costs, net   4,802       400       4,402     1101 %
Total operating expenses   101,562       55,377       46,185     83 %
Operating income (loss)   (24,053 )     2,092       (26,145 )   (1250 )%
Interest expense, net   (6,480 )     (6,696 )     216     (3 )%
Non-operating income (expense), net   (7,773 )     3,832       (11,605 )   (303 )%
(Loss) before income taxes   (38,306 )     (772 )     (37,534 )   4862 %
Income tax expense (recovery), net   1,725       (2,285 )     4,010     (175 )%
Net income (loss) $ (40,031 )   $ 1,513     $ (41,544 )   (2746 )%
Total net income (loss) attributable to:              
Stockholders of Tilray Brands, Inc.   (43,141 )     (322 )     (42,819 )   13298 %
Non-controlling interests   3,110       1,835       1,275     69 %
Other comprehensive gain (loss), net of tax              
Foreign currency translation gain (loss)   4,412       (188 )     4,600     (2447 )%
Comprehensive income (loss) $ (35,619 )   $ 1,325     $ (36,944 )   (2788 )%
Total comprehensive income (loss) attributable to:              
Stockholders of Tilray Brands, Inc.   (38,400 )     (489 )     (37,911 )   7753 %
Non-controlling interests   2,781       1,814       967     53 %
Weighted average number of common shares – basic1   133,340,533       106,027,190       27,313,343     26 %
Weighted average number of common shares – diluted1   133,340,533       106,027,190       27,313,343     26 %
Net loss per share – basic1 $ (0.32 )   $ (0.00 )   $ (0.32 )   10553 %
Net loss per share – diluted1 $ (0.32 )   $ (0.00 )   $ (0.32 )   10553 %
               
1The prior year share and amounts have been retrospectively adjusted to reflect the Reverse Stock Split, which became effective on December 2, 2025. See Note 1 (Basis of presentation and summary of significant accounting policies) within the Form 10-Q for the period ended August 31, 2026.
               

Condensed Consolidated Statements of Cash Flows              
  For the three months ended        
  August 31,   August 31,   Change   % Change
(in thousands of US dollars) 2026   2025   2026 vs. 2025
Cash provided by (used in) operating activities:              
Net income (loss) $ (40,031 )   $ 1,513     $ (41,544 )   (2746 )%
Adjustments for:              
Income tax expense (recovery), net   1,725       (2,285 )     4,010     (175 )%
Unrealized foreign exchange (gain) loss   4,524       (2,328 )     6,852     (294 )%
Amortization   18,638       15,561       3,077     20 %
Accretion of convertible debt discount   1,465       1,976       (511 )   (26 )%
Unrealized (gain) loss on digital assets   (46 )     8       (54 )   (675 )%
Other non-cash items   (1,745 )     282       (2,027 )   (719 )%
Stock-based compensation   6,584       5,052       1,532     30 %
Loss (gain) on long-term investments   27       (39 )     66     (169 )%
Loss on derivative instruments   —       3,670       (3,670 )   (100 )%
Change in fair value of contingent consideration   —       (15,000 )     15,000     (100 )%
Change in non-cash working capital:              
Accounts receivable   (1,319 )     14,414       (15,733 )   (109 )%
Prepaids and other current assets   1,004       (7,133 )     8,137     (114 )%
Inventory   (27,781 )     (11,905 )     (15,876 )   133 %
Accounts payable and accrued liabilities   20,414       (5,127 )     25,541     (498 )%
Net cash used in operating activities   (16,541 )     (1,341 )     (15,200 )   1133 %
Cash provided by (used in) investing activities:              
Investment in capital and intangible assets   (11,009 )     (9,523 )     (1,486 )   16 %
Proceeds from disposal of capital and intangible assets   101       293       (192 )   (66 )%
Investment in digital assets   —       (1,000 )     1,000     (100 )%
Sale (purchase) of marketable securities, net   2,242       34,697       (32,455 )   (94 )%
Proceeds from long-term investments   133       —       133     NM
Business acquisitions, net of cash acquired   (720 )     —       (720 )   NM
Net cash used in investing activities   (9,253 )     24,467       (33,720 )   (138 )%
Cash provided by (used in) financing activities:              
Share capital issued, net of cash issuance costs   22,338       22,491       (153 )   (1 )%
Repayment of long-term debt   (5,846 )     (2,653 )     (3,193 )   120 %
Repayment of lease liabilities   (2,438 )     (994 )     (1,444 )   145 %
Net (increase) decrease in bank indebtedness   (87 )     1,004       (1,091 )   (109 )%
Net cash provided by financing activities   13,967       19,848       (5,881 )   (30 )%
Effect of foreign exchange on cash and cash equivalents   828       188       640     340 %
Net increase (decrease) in cash and cash equivalents   (10,999 )     43,162       (54,161 )   (125 )%
Cash and cash equivalents, beginning of period   229,342       221,666       7,676     3 %
Cash and cash equivalents and restricted cash, end of period $ 218,343     $ 264,828     $ (46,485 )   (18 )%
               

Net Revenue by Operating Segment              
  For the three months ended   For the three months ended
(In thousands of U.S. dollars) August 31, 2026   % of Total
Revenue
  August 31, 2025   % of Total
Revenue
Beverage business $ 101,496     39%   $ 55,739     27%
Cannabis business   56,109     22%     64,511     31%
Distribution business   84,266     33%     74,007     35%
Wellness business   15,276     6%     15,244     7%
Total net revenue $ 257,147     100%   $ 209,501     100%
               
               
Net Revenue by Operating Segment in Constant Currency            
               
  For the three months ended   For the three months ended
  August 31, 2026       August 31, 2025    
(In thousands of U.S. dollars) as reported in constant currency   % of Total
Revenue
  as reported in constant currency   % of Total
Revenue
Beverage business $ 101,777     39%   $ 55,739     27%
Cannabis business   56,873     22%     64,511     31%
Distribution business   85,188     33%     74,007     35%
Wellness business   15,433     6%     15,244     7%
Total net revenue $ 259,271     100%   $ 209,501     100%
               
               
Net Cannabis Revenue by Market Channel              
  For the three months ended   For the three months ended
(In thousands of U.S. dollars) August 31, 2026   % of Total
Revenue
  August 31, 2025   % of Total
Revenue
Revenue from Canadian medical cannabis $ 4,717     8%   $ 6,146     10%
Revenue from Canadian adult-use cannabis   53,564     95%     64,067     99%
Revenue from wholesale cannabis   673     1%     4,155     6%
Revenue from international cannabis   16,237     29%     13,367     21%
Less excise taxes   (19,082 )   (33)%     (23,224 )   (36)%
Total $ 56,109     100%   $ 64,511     100%
               
               
Net Cannabis Revenue by Market Channel in Constant Currency            
  For the three months ended   For the three months ended
  August 31, 2026       August 31, 2025    
(In thousands of U.S. dollars) as reported in constant currency   % of Total
Revenue
  as reported in constant currency   % of Total
Revenue
Revenue from Canadian medical cannabis $ 4,804     8%   $ 6,146     10%
Revenue from Canadian adult-use cannabis   54,575     96%     64,067     99%
Revenue from wholesale cannabis   685     1%     4,155     6%
Revenue from international cannabis   16,252     29%     13,367     21%
Less excise taxes   (19,443 )   (34)%     (23,224 )   (36)%
Total $ 56,873     100%   $ 64,511     100%
               

Other Financial Information: Key Operating Metrics      
  For the three months ended
  August 31,   August 31,
(in thousands of U.S. dollars) 2026   2025
Net beverage revenue $ 101,496     $ 55,739  
Net cannabis revenue   56,109       64,511  
Distribution revenue   84,266       74,007  
Wellness revenue   15,276       15,244  
Beverage costs   59,489       34,413  
Cannabis costs   34,087       41,241  
Distribution costs   75,143       66,008  
Wellness costs   10,919       10,370  
Gross profit   77,509       57,469  
Beverage gross margin   41 %     38 %
Cannabis gross margin   39 %     36 %
Distribution gross margin   11 %     11 %
Wellness gross margin   29 %     32 %
Adjusted EBITDA $ 9,205     $ 10,181  
Cash and cash equivalents, restricted cash and marketable securities as at the period ended:   221,390       264,828  
Working capital as at the period ended: $ 376,903     $ 433,508  
       
Other Financial Information: Gross Margin and Adjusted Gross Margin                
  For the three months ended August 31, 2026
(In thousands of U.S. dollars) Beverage   Cannabis   Distribution   Wellness   Total
Net revenue $ 101,496     $ 56,109     $ 84,266     $ 15,276     $ 257,147  
Cost of goods sold   59,489       34,087       75,143       10,919       179,638  
Gross profit   42,007       22,022       9,123       4,357       77,509  
Gross margin   41 %     39 %     11 %     29 %     30 %
                   
  For the three months ended August 31, 2025
(In thousands of U.S. dollars) Beverage   Cannabis   Distribution   Wellness   Total
Net revenue $ 55,739     $ 64,511     $ 74,007     $ 15,244     $ 209,501  
Cost of goods sold   34,413       41,241       66,008       10,370       152,032  
Gross profit   21,326       23,270       7,999       4,874       57,469  
Gross margin   38 %     36 %     11 %     32 %     27 %
                   

Other Financial Information: Adjusted Earnings Before Interest, Taxes and Amortization        
  For the three months ended        
  August 31,   August 31,   Change   % Change
(In thousands of U.S. dollars) 2026   2025   2026 vs. 2025
Net income (loss) $ (40,031 )   $ 1,513     $ (41,544 )   (2746 )%
Income tax expense (recovery), net   1,725       (2,285 )     4,010     (175 )%
Interest expense, net   6,480       6,696       (216 )   (3 )%
Non-operating expense (income), net   7,773       (3,832 )     11,605     (303 )%
Amortization   18,638       15,561       3,077     20 %
Stock-based compensation   6,584       5,052       1,532     30 %
Change in fair value of contingent consideration   —       (15,000 )     15,000     (100 )%
Project 420 business optimization   —       200       (200 )   (100 )%
Litigation costs, net of recoveries   787       1,007       (220 )   (22 )%
Restructuring costs   2,447       869       1,578     182 %
Transaction costs, net   4,802       400       4,402     1101 %
Adjusted EBITDA $ 9,205     $ 10,181     $ (976 )   (10 )%
               
Other Financial Information: Adjusted cash operating income (loss)              
  For the three months ended        
  August 31,   August 31,   Change   % Change
  2026   2025   2026 vs. 2025
Operating income (loss) $ (24,053 )   $ 2,092     $ (26,145 )   (1250 )%
Change in fair value of contingent consideration   —       (15,000 )     15,000     (100 )%
Amortization   18,638       15,561       3,077     20 %
Stock-based compensation   6,584       5,052       1,532     30 %
Adjusted cash operating income (loss) $ 1,169     $ 7,705     $ (6,536 )   (85 )%
               
Other Financial Information: Adjusted net income (loss) and Adjusted net income (loss) per share (“Adjusted EPS”)    
  August 31,   August 31,   Change   % Change
  2026   2025   Change
Net loss attributable to stockholders of Tilray Brands, Inc. $ (43,141 )   $ (322 )   $ (42,819 )   13298 %
Non-operating expense (income), net   7,773       (3,832 )     11,605     (303 )%
Amortization   18,638       15,561       3,077     20 %
Stock-based compensation   6,584       5,052       1,532     30 %
Deferred income tax expense (benefits), net   (2,344 )     (2,537 )     193     (8 )%
Accretion of convertible debt discount   1,465       1,976       (511 )   (26 )%
Change in fair value of contingent consideration   —       (15,000 )     15,000     (100 )%
Project 420 business optimization   —       200       (200 )   (100 )%
Litigation costs, net of recoveries   787       1,007       (220 )   (22 )%
Restructuring costs   2,447       869       1,578     182 %
Transaction costs, net   4,802       400       4,402     1101 %
Adjusted net income (loss) $ (2,989 )   $ 3,374     $ (6,363 )   (189 )%
Adjusted net income (loss) per share – basic and diluted $ (0.02 )   $ 0.03     $ (0.05 )   (167 )%
               
Other Financial Information: Free Cash Flow              
  For the three months ended        
  August 31,   August 31,   Change   % Change
(In thousands of U.S. dollars) 2026   2025   2026 vs. 2025
Net cash used in operating activities $ (16,541 )   $ (1,341 )   $ (15,200 )   1133 %
Less: investments in capital and intangible assets, net   (10,908 )     (9,230 )     (1,678 )   18 %
Free cash flow $ (27,449 )   $ (10,571 )   $ (16,878 )   160 %
Add: growth CAPEX   3,025       3,009       16     1 %
Add: cash paid for litigation settlements   1,000       2,804       (1,804 )   (64 )%
Adjusted free cash flow $ (23,424 )   $ (4,758 )   $ (18,666 )   392 %
               

The new generation of Pulsar Max introduces ISO 15118-ready hardware designed to support evolving European AFIR charging requirements, alongside built-in RFID and Ethernet connectivity

BARCELONA, Spain, Oct. 08, 2026 (GLOBE NEWSWIRE) — Wallbox (NYSE: WBX), a global leader in electric vehicle (EV) charging and energy management solutions, today announced the European launch of the new generation of Pulsar Max, its compact AC charging solution for homes and shared residential environments.

Building on the success of the Pulsar platform, with more than 600,000 Wallbox chargers sold worldwide, the new Pulsar Max introduces enhanced connectivity, access control and future-ready hardware designed to make EV charging easier to install, connect and manage across a broader range of residential applications.

The new Pulsar Max incorporates ISO 15118-ready hardware, including an integrated Power Line Communication (PLC) hardware layer that provides the foundation for future vehicle-to-charger communication and smart charging capabilities. This architecture is designed to support AFIR-related use cases where applicable and help customers and installers prepare for evolving European charging requirements.

The new model also introduces built-in RFID authentication and Ethernet connectivity, complementing the existing Bluetooth and Wi-Fi options. Ethernet enables installers to connect multiple chargers through the same local network, while RFID authentication provides a simple way to identify and manage different users. Together, these capabilities make Pulsar Max particularly suited to shared residential environments such as condominiums and multi-tenant buildings.

“As electric mobility becomes mainstream, residential charging needs to evolve beyond simply delivering power to a vehicle,” said Eduard Castañeda, Chief Product and Technology Officer at Wallbox. “With the new Pulsar Max, we are combining the simplicity and compact design that have defined the Pulsar family with greater connectivity, user identification and hardware designed for the next generation of EV charging.”

Pulsar Max is available in three configurations: tethered versions offering 7.4 kW or 22 kW of charging power, and a 22 kW socket version. All variants can be managed through the Wallbox App and support Bluetooth, Wi-Fi and Ethernet connectivity, giving installers and drivers greater flexibility across different installation environments.

The new generation also retains Wallbox’s intelligent energy management capabilities, including the ability to charge using surplus solar energy. Pulsar Max is backed by a five-year product warranty, subject to the terms and conditions of sale, reinforcing Wallbox’s focus on reliability and long-term residential charging.

The new Pulsar Max is expected to be available across European markets from November 2026, with rollout beginning progressively across the region.

About Wallbox

Wallbox is a global technology company, dedicated to changing the way the world uses energy. Wallbox creates advanced electric vehicle charging and energy management systems that redefine the relationship between users and the network. Wallbox goes beyond charging electric vehicles to give users the power to control their consumption, save money and live more sustainably. Wallbox offers a complete portfolio of charging and energy management solutions for residential, semi-public, and public use in more than 100 countries around the world. Founded in 2015 in Barcelona, where the company’s headquarters are located, Wallbox currently has offices across Europe, Asia, and America. For more information, visit www.wallbox.com

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Wallbox intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release other than statements of historical fact should be considered forward-looking statements, including, without limitation, statements regarding Wallbox’s expected future operating results and financial position, growth, profitability and cost optimization, including the expected impact of Wallbox’s renewed capital structure; industry and company growth, and Wallbox’s business strategy and plans and related reinforcement of Wallbox’s sales and service organization. The words “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “focus,” “forecast,” “intend,” “likely,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to: Wallbox’s history of operating losses; risks related to the restructuring plan, including Wallbox’s inability to achieve projected operating improvements following the restructuring; the adoption and demand for electric vehicles including the success of alternative fuels, changes to rebates, tax credits and the impact of government incentives or reduction thereof; political and economic uncertainty and macroeconomic factors, such as impacts from tariffs and trade barriers, geopolitical conflicts, consumer spending, inflation and foreign exchange rates; the accuracy of Wallbox’s forecasts and projections including those regarding its market opportunity; competition; risks related to losses or disruptions in Wallbox’s supply or manufacturing partners; Wallbox’s reliance on the third-parties outside of its control; risks related to Wallbox’s technology, intellectual property and infrastructure; executive orders and regulatory changes under the U.S. political administration and uncertainty therefrom, as well as the other important factors discussed under the caption “Risk Factors” in Wallbox’s Annual Report on Form 20-F for the fiscal year ended December 31, 2025, as such factors may be updated from time to time in its other filings with the Securities and Exchange Commission (the “SEC”), accessible on the SEC’s website at www.sec.gov and the Investor Relations section of Wallbox’s website at investors.wallbox.com. Any such forward-looking statements represent management’s estimates as of the date of this press release. Any forward-looking statement that Wallbox makes in this press release speaks only as of the date of such statement. Except as required by law, Wallbox disclaims any obligation to update or revise, or to publicly announce any update or revision to, any of the forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Wallbox Public Relations Contact:
Albert Cabanes
Public Relations
Press@wallbox.com

VANCOUVER, British Columbia, Oct. 08, 2026 (GLOBE NEWSWIRE) — Endeavour Silver Corp. (“Endeavour” or the “Company”) (NYSE: EXK; TSX: EDR) reports third quarter 2026 production of 2,096,545 silver ounces (“oz”), 10,126 gold oz, and in combination with base metals, a silver equivalent(1) production of 3.6 million oz. Year-to-date production was 5,915,874 silver oz and 32,340 gold oz for a total silver equivalent(1) production of 10.4 million oz. All dollar amounts are in US dollars ($).

“Despite temporary operational disruptions, we are encouraged by our underlying metrics in the third quarter, with the Terronera plant reaching optimal processing performance and the Kolpa expansion exceeding expectations.” commented Dan Dickson, Chief Executive Officer. “This performance reflects the focus and resilience of our teams, who responded effectively to temporary operational disruptions while maintaining a strong commitment to safe production. With these challenges successfully managed and with our operations continuing to advance, we are well positioned to build on this progress and carry positive momentum into the fourth quarter.”

Q3 2026 Production Overview

  • Consistent Throughput: Consolidated throughput and grades were consistent with throughput and grades in Q2 2026. Metal recoveries have further improved through continued process refinement, resulting in consolidated production in line with plan and silver equivalent(1) production of 3.6 million oz, compared to 3.4 million produced in Q2 2026.
  • Kolpa Further Increases Throughput: Throughput increased in Q3 2026 to 256,052 tonnes, compared to 233,408 tonnes in Q2 2026, reflecting the continued benefits of the plant expansion commissioned at the end of Q1 2026.
  • Blockade and Suspension of Operations at Terronera Mine: Operations at the Terronera mine were suspended from August 12 to August 24, 2026, resulting in a slightly lower Q3 throughput of 165,171 tonnes compared to 175,729 tonnes in Q2 2026. During the quarter, metal recoveries improved with optimization and refinement within the plant. Sill development commenced in the high-grade zones of Terronera.
  • Guanaceví Temporary Reduction of Capacity: The mill was taken offline on September 21 to replace the primary mill head and trunnion, with repairs expected to be completed in the first half of October. During this period, processing has continued at a lower throughput. This resulted in lower than planned throughput for the quarter of 89,722 tonnes. Ore grades improved compared to the prior quarter; however, higher prices enable mining in lower grade areas, extending mine life.
  • Metal Sales and Inventories: Total sales of 1,900,368 silver oz and 9,499 gold oz during the third quarter. A total of 363,854 silver oz and 1,346 gold oz of bullion inventory and 59,547 silver oz and 306 gold oz in concentrate inventory were held as at September 30, 2026.

Q3 2026 Operations

Consolidated silver production was 2,096,545 oz in Q3 2026, slightly below plan, and 19% higher than 1,766,926 oz produced in Q3 2025. Higher production is attributed to the higher silver production from Kolpa and the additional 710,670 oz of silver contributed by Terronera, which achieved commercial production on October 1, 2025. These higher contributions were partially offset by the sale of Bolañitos which was finalized on January 15, 2026. Silver production at Guanaceví was 31% lower in Q3 2026 compared to Q3 2025, predominantly due to 24% lower silver grades and 10% lower throughput.

Consolidated gold production was 10,126 oz in Q3 2026, 39% higher than 7,285 oz produced in Q3 2025. Higher production is primarily attributable to the addition of 7,157 oz from Terronera, partially offset by the sale of Bolañitos. Gold production at Guanacevi was 7% lower than Q3 2025, predominantly due to the 10% lower throughput and 1% lower gold grade. 

Terronera’s Q3 2026 production was slightly below plan, reflecting lower throughput during the blockade in August. In September 2026, following the resolution of the blockade, Terronera processed 60,313 tonnes and produced 299,398 oz of silver and 2,472 oz of gold during the month.

During Q3 2026, Terronera recoveries averaged 88.0% for silver and 75.0% for gold, slightly above Q1 and Q2 2026 and in line with plan. Recoveries improved during the quarter, as shown in the monthly production results table below, trending from 85.6% in July and 86.2% in August achieving a recovery of 91.1% in September reflecting the success of optimization work undertaken during the period. Ore grades of 152 grams per tonne (gpt) compared to 126 in Q2 2026 for silver and 1.80 gpt of gold compared to 1.87 in Q2 2026 for gold were in line with plan for the quarter. Grades improved as planned with sill development in higher grade zones commencing during the quarter.

Guanaceví’s throughput was 10% lower than Q3 2025 due to the reduction in capacity in September. Grades were higher than in the preceding quarters but lower than Q3 2025 due to the planned mining sequence through lower-grade areas of the deposit and higher than planned dilution. Supplies of local third-party mill feed continued to supplement Guanaceví production, amounting to 33% of quarterly throughput.

Kolpa’s throughput in Q3 2026 was 256,052 tonnes producing 682,903 oz of silver, compared to 233,408 tonnes producing 633,288 oz of silver in Q2 2026, following the plant ramp-up to 2,500 tonnes per day at the end of Q1 2026. The processed material in Q3 2026 averaged grades of 92 g/t silver, 2.67% lead, 2.08% zinc and 0.25% copper. Despite the slightly lower grades, due to the significant increase in throughput, production of silver exceeded plan while production of base metals remained in line with plan.

Updated Guidance

With operational interruptions at Terronera and Guanaceví during the quarter, the Company will be performing recalculations of full year production and cost guidance. Production for the full year is expected to be at or slightly below the low end of the guided range. A guidance update will be provided with the third quarter earnings release on November 9, 2026.

Consolidated Production Highlights for the Three and Nine Months Ended September 30, 2026

Three Months Ended September 30   Nine Months Ended September 30
2026 2025 % Change   2026 2025 % Change
510,944 400,245 28% Throughput (tonnes) 1,477,177 913,580 62%
2,096,545 1,766,926 19% Silver ounces produced 5,915,874 4,456,455 33%
10,126 7,285 39% Gold ounces produced 32,340 23,379 38%
6,504 5,664 15% Lead tonnes produced 17,650 9,167 93%
4,558 3,666 24% Zinc tonnes produced 11,389 5,982 90%
143 120 20% Copper tonnes produced 336 178 89%
2,031,425 1,725,317 18% Payable silver ounces produced 5,719,334 4,373,087 31%
9,852 7,151 38% Payable gold ounces produced 31,370 22,978 37%
3,611,034 3,037,156 19% Silver equivalent ounces produced1 10,390,771 7,438,645 40%
1,900,368 1,762,484 8% Silver ounces sold 5,596,696 4,441,848 26%
9,499 7,478 27% Gold ounces sold 31,265 23,722 32%

1 Silver equivalent for 2026 is calculated using 90 silver oz to 1 gold oz; 45 silver oz to 1 lead tonne; 61 silver oz to 1 zinc tonne; 238 silver oz to 1 copper tonne. Silver equivalent for 2025 is calculated using 80 silver oz to 1 gold oz; 60 silver oz to 1 lead tonne; 85 silver oz to 1 zinc tonne; 300 silver oz to 1 copper tonne ratios.
Bolañitos mine was sold January 15, 2026, and is included in the consolidated results above.

Production Tables for the Three Months Ended September 30, 2026, by mine

Three Months Ended September 30, 2026 Terronera Guanaceví Kolpa
Tonnes processed 165,171 89,722 256,052
Tonnes per day 1,795 975 2,783
Silver ounces produced 710,670 702,972 682,903
Silver grade gpt 152 257 92
Silver recovery 88.0% 94.9% 90.3%
Gold ounces produced 7,157 2,969 –
Gold grade gpt 1.80 1.06 –
Gold recovery 75.0% 96.8% –
Lead tonnes produced – – 6,504
Lead grade % – – 2.67%
Lead recovery % – – 95.2%
Zinc tonnes produced – – 4,558
Zinc grade % – – 2.08%
Zinc recovery % – – 85.7%
Copper tonnes produced – – 143
Copper grade % – – 0.25%
Copper recovery % – – 22.7%
Silver equivalent ounces produced1 1,354,759 970,205 1,286,070

Totals may not add up due to rounding.
1 Silver equivalent for 2026 is calculated using 90 silver oz to 1 gold oz; 45 silver oz to 1 lead tonne; 61 silver oz to 1 zinc tonne; 238 silver oz to 1 copper tonne.

Terronera Production by Month for the Three Months Ended September 30, 2026

The table below presents monthly production at Terronera during the third quarter. Metal recoveries improved throughout the quarter as processing activities were refined and optimized. Metal grades also strengthened as sill development commenced in higher-grade zones during the third quarter.

Three Months Ended September 30, 2026 July August September Total
Tonnes processed 65,307 39,551 60,313 165,171
Tonnes per day 2,107 1,276 2,010 1,795
Silver ounces produced 230,405 180,868 299,398 710,670
Silver grade gpt 128 165 169 152
Silver recovery 85.6% 86.2% 91.1% 88.0%
Gold ounces produced 3,049 1,635 2,472 7,157
Gold grade gpt 1.95 1.73 1.67 1.80
Gold recovery 74.3% 74.5% 76.3% 75.0%
Silver equivalent ounces produced1 504,836 328,042 521,881 1,354,759

1 Silver equivalent for 2026 is calculated using 90 silver oz to 1 gold oz; 45 silver oz to 1 lead tonne; 61 silver oz to 1 zinc tonne; 238 silver oz to 1 copper tonne.

Production Tables for the Nine Months Ended September 30, 2026, by mine

Nine Months Ended September 30, 2026 Terronera Guanaceví Kolpa
Tonnes processed 516,318 285,684 661,187
Tonnes per day 1,891 1,046 2,422
Silver ounces produced 1,852,318 2,198,851 1,846,309
Silver grade gpt 130 259 96
Silver recovery 86.0% 92.6% 90.5%
Gold ounces produced 23,301 8,547 –
Gold grade gpt 1.91 1.00 –
Gold recovery 73.4% 92.7% –
Lead tonnes produced – – 17,650
Lead grade % – – 2.81%
Lead recovery % – – 94.9%
Zinc tonnes produced – – 11,389
Zinc grade % – – 2.03%
Zinc recovery % – – 84.7%
Copper tonnes produced – – 336
Copper grade % – – 0.23%
Copper recovery % – – 22.1%
Silver equivalent ounces produced1 3,949,375 2,968,054 3,410,577

1 Silver equivalent for 2026 is calculated using 90 silver oz to 1 gold oz; 45 silver oz to 1 lead tonne; 61 silver oz to 1 zinc tonne; 238 silver oz to 1 copper tonne.
Bolañitos mine was sold January 15, 2026, and is not included in the breakdown above.
Totals may not add up due to rounding.

Management Change

The Company also announces that Greg Blaylock will be departing from his role as Vice President, Operations. The Company thanks Mr. Blaylock for his dedicated service and wishes him every success in the future.

About Endeavour Silver

Endeavour is a mid-tier silver producer with three operating mines in Mexico and Peru and a robust pipeline of exploration projects across Mexico, Chile, and the United States. With a proven track record of discovery, development, and responsible mining, Endeavour is driving organic growth and creating lasting value on its path to becoming a leading senior silver producer.

Qualified Person

Dale Mah, P.Geo., Vice President Corporate Development, a qualified person under NI 43-101, has approved the scientific and technical information related to operations matters in this news release.

Q3 2026 Financial Results and Conference Call

Q3 2026 financial results will be released after market close on Monday, November 9, 2026, and Management will host a conference call the next day, Tuesday, November 10, 2026, at 9:00 a.m. Pacific Time / 11:00 a.m. Eastern Standard Time to discuss the results.

Date:  Tuesday, November 10, 2026
   
Time: 9:00am Pacific Time / 11:00am Eastern Standard Time
   
Telephone: Canada & US + 1-833-752-3348
International + 1-647-846-2804
   
Replay: Canada & US +1- 855-669-9658
International +1-412-317-0088 
Access code is 5403106; audio replay will be available on the Company’s website
   

Contact Information

Allison Pettit
Vice President, Investor Relations
Email: apettit@edrsilver.com
Website: www.edrsilver.com

Cautionary Note Regarding Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicable Canadian securities legislation. Such forward-looking statements and information herein include, but are not limited to, statements regarding the timing for completion of repairs at the Guanaceví mill; the Company’s positioning; updates to guidance and the timing thereof; expected production; the Company’s plans to drive organic growth, create lasting value and become a leading senior silver producer; and the timing and results of various activities. The Company does not intend to and does not assume any obligation to update such forward-looking statements or information, other than as required by applicable law.

Forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, production levels, performance or achievements of Endeavour and its operations to be materially different from those expressed or implied by such statements. Such factors include but are not limited to disruptions and delays due to blockades, protests, demonstrations and similar actions; unexpected changes in production and cost guidance; the ongoing effects of inflation and supply chain issues on mine economics; the failure to complete repairs at the Guanaceví mill in a timely manner or at the expected cost; the effectiveness of alternative processing methods; a greater-than-anticipated adverse impact on production levels and costs; changes in national and local governments’ legislation, taxation, controls, regulations and political or economic developments in Canada, Chile, the USA, Mexico and Peru; financial risks due to precious metals prices; operating or technical difficulties in mineral exploration, development and mining activities; risks and hazards of mineral exploration, development and mining (including, but not limited to environmental hazards, industrial accidents, unusual or unexpected geological conditions, pressures, cave-ins and flooding); inadequate insurance, or inability to obtain insurance; availability of and costs associated with mining inputs and labour; the speculative nature of mineral exploration and development; diminishing quantities or grades of mineral reserves as properties are mined; risks in obtaining necessary licenses and permits; fluctuations in the prices of silver and gold; fluctuations in currency markets (particularly the Mexican peso, Peruvian sol, Chilean peso, Canadian dollar and U.S. dollar); and challenges to the Company’s title to properties; as well as those factors described in the section “Risk Factors” contained in the Company’s most recent form 40F/Annual Information Form filed with the S.E.C. and Canadian securities regulatory authorities.

Forward-looking statements are based on assumptions management believes to be reasonable, including but not limited to: the continued operation of the Company’s mining operations, no material adverse change in the market price of commodities, forecasted mine economics, mining operations will operate and the mining projects will be completed in accordance with management’s expectations and achieve their stated production outcomes, and such other assumptions and factors as set out herein. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or information, there may be other factors that cause results to be materially different from those anticipated, described, estimated, assessed or intended. There can be no assurance that any forward-looking statements or information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements or information. Accordingly, readers should not place undue reliance on forward-looking statements or information.

CALGARY, Alberta, Oct. 08, 2026 (GLOBE NEWSWIRE) — Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug discovery company developing novel therapeutics for autism spectrum disorder (“ASD”) and related neurodevelopmental disorders, is pleased to announce preliminary results from its preclinical study of MB-204 in the Shank3Δex13-16 mouse model, a model associated with Phelan-McDermid syndrome. The study was conducted in collaboration with Dr. Julie Le Merrer and Dr. Jérôme Becker at the iBraiN Institute in Tours, France, and evaluated MB-204 at oral doses of 1 mg/kg and 2.5 mg/kg compared with Istradefylline at 1 mg/kg, the highest dose tested that did not affect locomotion.   Animals were studied for one to three hours post dosing. Istradefylline is a clinically approved drug for the treatment of Parkinson’s Disease.

Preliminary Results Demonstrate Broad Activity of MB-204

The preliminary results indicate that MB-204 produced improvements across multiple behavioural endpoints associated with repetitive and abnormal behaviours in the Shank3 model. MB-204 continues to demonstrate activity across increasingly diverse genetic models, supported by the emerging Shank3 data, potentially advancing a broader therapeutic opportunity as the company approaches human clinical development.

Key Data Highlights

  • Low-dose MB-204 (1 mg/kg) matched or exceeded Istradefylline across the majority of measured endpoints: performance was matched on the number and time of nose contacts, number and time of paw contacts, the number of grooming episodes and number of same arm returns (SARs) in the Y-maze test of repetitive behaviour.
  • Low dose of MB-204 demonstrated superior performance to Istradefylline on the mean duration of paw contacts, number of following episodes and the number of spontaneous and alternate arm returns (AARs) in the Y-maze. Only the number of rearing episodes was Istradefylline more effective than low dose MB-204.
  • High-dose MB-204 (2.5 mg/kg) was superior to Istradefylline across the majority of measured endpoints: performance was matched only in the number of grooming episodes, rearing episodes and SARs. On all other endpoints as per above, MB-204 was superior to Istradefylline.
  • All treatments showed demonstrable improvement in multiple behavioural endpoints over untreated Shank3 animals except for the number of following episodes and AARs in the Istradefylline treated animals.
  • The study also provides a direct head-to-head comparison between MB-204 and its parent compound, Istradefylline, supporting the Company’s objective of demonstrating differentiated activity for its proprietary fluorinated derivative.
  • Final statistical analyses and additional endpoints remain pending.

* The Company cautions that these are preliminary preclinical findings and that additional analyses may modify the interpretation of individual endpoints.

“This is the third model where MB-204 has had a profound effect on socialization and repetitive behaviours,” said Drs. Le Merrer and Becker, “which are the key hallmarks of autism. MB-204 nearly reversed all the social deficits and repetitive behaviours in the Shank3 model as we previously saw in the Oprm1 mouse model and Rett syndrome models. This study also confirms the superiority of MB-204 over the parental drug Istradefylline in a head-to-head study. Together with the recent Fragile X results, the data suggests MB-204 may be a pan-spectrum treatment for autism. We look forward to presenting the data in upcoming conferences and publishing the data on MB-204 for the wider scientific community to review.”

Expanding Evidence Across Genetically Distinct Neurodevelopmental Models

The Shank3 findings add to a growing body of preclinical evidence generated for MB-204 across genetically distinct models of neurodevelopmental disorders.

Marvel has previously reported positive preclinical results in:

  • Oprm1: an autism model in which MB-204 demonstrated restoration of social interaction and improvements in repetitive behaviours following oral administration. 
  • Mecp2/Rett syndrome: MB-204 demonstrated near-reversal of social and behavioural deficits and outperformed Trofinetide across multiple endpoints in the Company’s disclosed preclinical study. 
  • Fragile X (Fmr1): MB-204 produced statistically significant improvements in behavioural and cognitive function, including a carry-over effect after treatment cessation. 
  • Shank3: representing another genetically distinct model associated with autism and Phelan-McDermid syndrome.

The Company believes that the emergence of consistent behavioural activity across models associated with different underlying genetic causes may be important in evaluating the potential breadth of MB-204’s mechanism and therapeutic application.

“The Shank3 results are particularly encouraging because they add another genetically distinct model to the growing body of evidence supporting MB-204,” said Dr. Mark Williams, President and Chief Science Officer of Marvel Biosciences. “Together with our previously reported Oprm1, Mecp2 and Fragile X results, these findings continue to support our hypothesis that targeting the adenosine A2A receptor may address behavioural and social deficits across multiple neurodevelopmental disorders. We look forward to completing the statistical analysis and presenting the full dataset to the scientific community.”

About Marvel Biosciences Corp.

Marvel Biosciences Corp. (TSXV:MRVL | OTCQB:MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company. The Company is developing MB-204, a novel fluorinated derivative of the approved anti-Parkinson’s drug Istradefylline, the only clinically approved adenosine A2a antagonist. A significant and growing body of scientific evidence suggests drugs that block the adenosine A2a receptor, such as MB-204, could be useful in treating other neurological diseases such as autism, depression and Alzheimer’s Disease. The Company is actively investigating its potential in addressing other neurodevelopmental disorders, such as Rett Syndrome and Fragile X Syndrome, to expand its therapeutic reach.

Contact Information: Marvel Biosciences Corp.

J. Roderick (Rod) Matheson, Chief Executive Officer
Email: rod@marvelbiosciences.com
Dr. Mark Williams, President and Chief Science Officer
Email: mark@marvelbiosciences.com
Tel: 403 770 2469

Website: www.marvelbiotechnology.com    |   Twitter/X   |   LinkedIn

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release. All information contained in this news release with respect to the Company and its subsidiary,(collectively, the “Parties”) were supplied by Marvel, respectively, for inclusion herein and each parties’ directors and officers have relied on each other for any information concerning such Party.

This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company and include other risks detailed from time to time in the filings made by the Company under securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events on the terms will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.

SUDBURY, Ontario, Oct. 08, 2026 (GLOBE NEWSWIRE) — Magna Mining Inc. (TSX: NICU) (OTCQX: MGMNF) (FSE: 8YD) (“Magna” or the “Company”) is pleased to announce the results of a Preliminary Economic Assessment (“PEA”) prepared in accordance with National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“NI 43-101”) for the restart of the fully-permitted Levack Mine (“Levack”), located in the North Range of the Sudbury Basin, northeastern Ontario, Canada. All amounts are expressed in Canadian dollars unless otherwise indicated.

Levack PEA Highlights:

  • Solid production profile and short time frame to commercial production: The Levack PEA contemplates underground mining of 5.75 million short tons with 7.3 years of commercial production and average annual payable copper equivalent (“CuEq”)1,2 production of 36.8 million pounds (“lbs”) at all-in sustaining costs (“AISC”) of US$3.71 per CuEq payable pound2 and commercial production anticipated in mid-2028.
  • Low initial capital and robust pre-commercial production operating cash flows: Initial capital costs from January 1, 2027 to the start of commercial production are estimated to be $70.1 million, after incorporating equipment financing timing effects. This initial capital is estimated to be offset by refundable tax credits3 of approximately $5.6 million and expected pre-commercial production operating cash flow of approximately $55.9 million using base case price assumptions1, leaving a calculated net initial funding requirement of $8.6 million.
  • Rapid payback and robust base case economics: Assuming base case commodity prices, the Levack PEA estimates payback in 0.6 years with a base case after-tax Internal Rate of Return (“IRR”) of 92.4% and an after-tax NPV7% of $227.0 million. Pre-tax cash flows in 2028 and 2029 are estimated to be approximately $96.5 million per year. Using September 2026 average commodity prices1, the after-tax NPV7% increases to $313.6 million and the IRR improves to 115.8%, with average pre-tax cash flows of approximately $120.6 million per year in 2028 and 2029.
  • Positive potential impact from the recently announced Productivity Mega Deduction:   Incorporation of the Productivity Mega Deduction (“PMD”)4 could reduce the estimated federal taxes payable over the life of mine. The Levack PEA after-tax NPV7% improves by $5.1 million to $232.1 million and the IRR increases to 99.2%, by reducing total federal taxes paid by $1.6 million and accelerating the utilization of certain tax deductions.

Additional opportunities: The potentially mineable resources in the Levack PEA are a subset of the updated Levack Mine Mineral Resource Estimate (MRE) which include additional resources within the No.7 Contact Zone and additional mineralization in the Morrison Footwall Cu-PGE Deposit compared to the Levack Mine MRE announced on November 18, 2025. The PEA does not include any potential production from the R2 Footwall Zone. See the news release dated September 17, 2026 for the most recent exploration results from the R2 Footwall Zone.

Formal approval to restart Levack Mine: Based on the results of the PEA (summarized in Table 1), and while acknowledging that there are no supporting mineral reserves with demonstrated economic viability, the Company’s Board of Directors has formally approved the plan to restart the Levack Mine, with underground development and surface construction activities expected to ramp up significantly over the coming months.

1 Base case price assumptions: US$5.10/lb Cu, US$8.00/lb Ni, US$20.00/lb Co, US$3,600/oz Au, US$1,500/oz Pt, US$1,200/oz Pd, US$45.00/oz Ag; CAD/USD $1.385. Illustrative spot price case assumptions based on September 2026 average prices: US$6.55/lb Cu, US$7.50/lb Ni, US$24.90/lb Co, US$4,320/oz Au, US$1,785/oz Pt, US$1,310/oz Pd, US$64.50/oz Ag; CAD/USD $1.370.
2 Payable CuEq production considers base case price assumptions and modeled recovery and payabilities for each metal.
3 Assumes $5.6 million in refundable tax credits via the Clean Technology Manufacturing Investment Tax Credit (CTM-ITC).
4 On September 15, 2026, the Canadian federal government announced the Productivity Mega Deduction (“PMD”), allowing businesses to immediately deduct the cost of a broad range of capital assets, rather than claiming those deductions over time. The PMD is subject to legislative approval.  

Jason Jessup, CEO of Magna, stated, “The PEA demonstrates Levack Mine’s potential as a low capital cost, high IRR project with a clear pathway to a rapid ramp-up to commercial production. The low capital intensity reflects the significant capital previously invested in the mine, as well as the current state of its existing infrastructure. The mine plan outlined in the study prioritizes higher-grade copper-precious metal footwall zones early in the mine life, generating meaningful pre-production revenue and supporting a strong IRR.

The Levack team embodies Magna’s core value of the Relentless Pursuit of Excellence, and I am confident we will continue to optimize the mine plan while incorporating new mineralized zones, including the R2 Zone, with the objective of extending mine life and further enhancing project economics. Given the strong IRR and operating cash flows demonstrated in the PEA, together with Magna’s treasury position, the Board of Directors has approved the investment to formally restart the Levack Mine. This represents an important next step in Magna’s growth toward becoming a mid-tier producer.”

Table 1: Key Levack PEA Project Metrics

Production Profile   Unit
Commercial production life 7.3 years
Mining rate1 2,141 tons per day
Total mining inventory 5,747,819 tons
CuEq head grade1,5 3.42 %
Avg. annual copper production1 12.9 million payable lbs
Avg. annual nickel production1 10.9 million payable lbs
Avg. annual precious metals production1 21.4 koz Pt+Pd+Au
Avg. annual CuEq production1,5 36.8 million payable lbs
Operating Costs   Unit
Production costs LOM $157.80 C$ per ton processed
Cash costs US$3.23 US$ per CuEq payable lb
All-in sustaining costs US$3.71 US$ per CuEq payable lb
Capital Costs    
Initial capital2 $70.1 C$ million
LOM Sustaining capital $168.0 C$ million
Project Economics Base Case3 Spot Price Case4
Avg. annual operating cash flow (C$ million) $91.2 $114.1
Pre-tax NPV(7%) (C$ million) $312.1 $438.3
After-tax NPV(7%) (C$ million) $227.0 $313.6
After-tax IRR 92.4% 115.8%
After-tax cash flow LOM (C$ million) $326.9 $446.0
After-tax payback 0.6 years 0.4 years
After-tax NPV(7%) with PMD6 (C$ million) $232.1 $318.6
After-tax IRR with PMD6 99.2% 122.3%
     

1 Production averages cover commercial production from mid-2028 to 2035. CuEq head grade is on a contained basis covering Life of Mine. CuEq determined using base case metal price assumptions. Tons are short tons (2,000 lb).
2 January 2027-June 2028 pre-commercial production capital, after equipment financing timing effect; before operating cash flow and refundable tax credits. Payback is measured from January 1, 2028.
3 US$5.10/lb Cu, US$8.00/lb Ni, US$20.00/lb Co, US$3,600/oz Au, US$1,500/oz Pt, US$1,200/oz Pd, US$45.00/oz Ag; CAD/USD $1.385.
4 Illustrative spot-price case based on September 2026 average prices: US$6.55/lb Cu, US$7.50/lb Ni, US$24.90/lb Co, US$4,320/oz Au, US$1,785/oz Pt, US$1,310/oz Pd, US$64.50/oz Ag; CAD/USD $1.370.
5 See Tables Included with Figures 2 and 3 for grades and contribution of specific metals.
6 On September 15, 2026, the Canadian federal government announced the proposed Productivity Mega Deduction (“PMD”), which would permit the immediate deduction of certain eligible capital expenditures for income tax purposes. As the PMD has not yet been enacted into law, the benefit has been excluded from the base-case economic analysis and is presented separately as a sensitivity.

Figure 1: Location of Levack Mine and Key Sudbury Infrastructure

Figure 1

PEA Overview

The Levack Mine project, located in the North Range of the Sudbury Basin (Figure 1), is a brownfield redevelopment of the past-producing nickel-copper-precious metals (platinum, palladium, gold, silver) Levack Mine which was last operated in 2018. Topics covered in the PEA include the mining design basis, geotechnical design basis, hydrogeology and dewatering, mine access and design, mining method and stope design, development, production schedule, mobile fleet, workforce, ventilation, backfill, material handling and grade control. The PEA was prepared by AGP Mining Consultants Inc. with the assistance of Magna’s Projects team, as well as insights from current operations at the Company’s adjacent McCreedy West Mine. The PEA incorporates geological information collected by the Company as well as historic information from the previous underground mining operations at Levack.

Mine Plan and Production Schedule

The Levack PEA mine plan (summarized in Table 1) assumes go-forward capital spending begins on January 1, 2027 and ramps up over the first two years of production with commercial production anticipated in mid-2028 (Figure 2). At a target commercial production rate of approximately 2,200 short tons per day, the mine plan includes 5.75 million short tons and 7.3 years of commercial production.

The mineralized zones incorporated in the mine plan include the Footwall Copper zones, the Contact Nickel zones (the former Main, East and No.7 block models), and the Morrison Footwall Cu-PGE deposit (Figure 6). The 5.75 million short tons include diluted Indicated and Inferred mining inventory derived from the current Levack Mineral Resource Estimate. The R2 Footwall Zone is excluded from the PEA inventory and economics, as mineral resources have not yet been defined

The PEA is preliminary in nature and includes 2.1 million short tons of Inferred Mineral Resources that are considered too speculative geologically to have economic considerations applied to them that would enable them to be categorised as Mineral Reserves. The location and extent of historic mined-out stopes and voids remain uncertain, the effect on resource depletion, dilution, recovery and ground stability adjacent to historic workings remains a risk. There is no certainty that the PEA will be realised. Mineral Resources that are not Mineral Reserves do not have demonstrated economic viability.

Figure 2 shows annual mill feed by zone and contained CuEq head grade. Contained CuEq head grade uses base case metal prices, without recovery, payability, stream or cost deductions. Figure 3 shows payable metal production expressed as CuEq, using the modeled recoveries and payabilities. Precious metal head grades in Figure 2 are in troy ounces per short ton.

Figure 2: Levack PEA Production Schedule & Contained Copper Equivalent Grade

Figure 2_chart

Year Y 1 Y 2 Y 3 Y 4 Y 5 Y 6 Y 7 Y 8 Y 9
Material shipped (short tons)
82,372 620,640 776,880 775,408 780,343 775,307 786,211 797,453 353,205  
Contained Grades CuEq (%) 4.19 4.24 3.64 3.60 3.06 3.18 3.29 3.07 3.29  
Cu (%) 1.11 1.15 0.90 1.14 0.90 0.86 1.00 0.88 0.97  
Ni (%) 0.93 1.16 1.13 0.81 0.94 1.08 1.05 1.04 1.00  
Co (%) 0.023 0.034 0.035 0.021 0.029 0.033 0.032 0.032 0.028  
Au (ozt) 0.012 0.009 0.004 0.008 0.004 0.002 0.002 0.002 0.003  
Pt (ozt) 0.031 0.024 0.021 0.025 0.013 0.013 0.014 0.012 0.017  
Pd (ozt) 0.052 0.037 0.032 0.034 0.018 0.018 0.018 0.016 0.024  
Ag (ozt) 0.125 0.084 0.060 0.101 0.063 0.031 0.033 0.031 0.040  
                       

Figure 3: Levack PEA Copper Equivalent Payable Metal Production

Figure 3_chart

Year Y 1 Y 2 Y 3 Y 4 Y 5 Y 6 Y 7 Y 8 Y 9
Payable Metal CuEq (million lb) 4.86 38.27 40.05 39.35 33.16 34.33 36.27 33.83 16.17  
Cu (million lb) 1.60 12.58 12.13 15.42 11.86 11.37 13.63 11.81 5.75  
Ni (million lb) 1.03 10.31 12.46 8.28 9.92 11.56 11.31 11.29 4.81  
Co (million lb) 0.008 0.100 0.128 0.070 0.099 0.120 0.115 0.116 0.045  
Au (koz) 0.655 3.752 1.532 4.208 1.947 0.776 0.630 0.539 0.492  
Pt (koz) 1.458 8.486 8.992 10.922 5.478 5.480 6.002 5.016 3.251  
Pd (koz) 2.929 16.128 16.972 17.968 9.431 8.987 9.319 8.257 5.694  
Ag (koz) 3.067 21.476 16.722 28.241 17.855 8.177 6.388 6.385 6.729  
                       

Capital and Operating Costs

The Levack Mine benefits from significant pre-existing surface and underground infrastructure, much of which has been well-maintained since operations ceased in 2018 given Levack Mine provides secondary egress for the Company’s adjacent McCreedy West Mine, and more recently for other adjacent underground mining operations. Pre-existing infrastructure as well as capital invested prior to the end of 2026 is treated as sunk capital for the purposes of the PEA.

Estimated initial capital is C$70.1 million, including C$12.6 million of contingency. The estimate comprises capital expenditure from January 1, 2027 to June 30, 2028, reflecting the timing of equipment financing (Table 2). Estimated initial capital is presented after equipment financing timing effects. Deferred equipment purchase payments are included in subsequent years. The after-tax cash flow model incorporates the Clean Technology Manufacturing investment tax credits. Eligibility and receipt of those credits remain subject to the applicable requirements and the Company’s tax review. The mitigation from pre-production revenue and the benefit of refundable tax credits do not reduce the initial capital required but do help to decrease the net cash outlay at the end of the ramp-up period to an estimated C$8.6 million.

Estimated sustaining capital from commercial production on July 1, 2028 onward is C$168.0 million.

Table 2: Levack PEA Initial Capital Costs

Initial Capex   C$ million
Underground Capital    
Underground development   $27.8
Mobile fleet (after financing timing effects)   $10.3
Leasing interest expense   $0.6
Underground infrastructure   $5.7
Subtotal   $44.4
Surface Infrastructure Capital    
Water, waste management & closure   $4.1
Power distribution & ventilation   $4.0
Surface building upgrades   $1.5
Backfill plant & reticulation   $1.8
Shaft activation & hoist   $1.7
Subtotal   $13.1
Contingency   $12.6
Total initial capital (Jan 2027-Jun 2028)   $70.1
Refundable tax credits   -$5.6
Pre-commercial production operating cash flow   -$55.9
Net initial funding   $8.6
     

The Company’s adjacent McCreedy West Mine provides an operating cost and productivity benchmark. Average life-of-mine operating costs in the Levack PEA are C$157.80 per short ton processed (Table 3). Cash costs are US$3.23/lb payable CuEq and all-in sustaining costs are US$3.71/lb payable CuEq. Cash costs use the commercial production periods and exclude stream costs, which are already deducted from revenue. AISC adds estimated sustaining capital. These are non-GAAP measures and may not be comparable with similarly named measures used by other companies.

Table 3: Levack PEA Operating Costs

Operating Costs
LOM Unit
Mining Costs   $88.51 C$/ton shipped
Surface & Processing Costs   $54.27 C$/ton shipped
General & Site Administration Costs   $15.02 C$/ton shipped
Total Operating Costs   $157.80 C$/ton shipped
Total Cash Costs   US$3.23 US$/lb CuEq payable
AISC   US$3.71 US$/lb CuEq payable
       

Project Economics & Sensitivity

At the base-case prices in Table 4, recovered payable metal value comprises the following revenue share 34.8% copper, 46.0% nickel, 3.7% gold, 5.9% platinum, 8.1% palladium, 1.1% cobalt, 0.4% silver. The Levack PEA base case pre-tax NPV7% is C$312.1 million and the after-tax NPV7% is C$227.0 million, with an after-tax IRR of 92.4% and payback of 0.6 years. The after-tax NPV7% incorporates the Company’s current tax assumptions, including an estimated benefit of C$20.4 million LOM from the Clean Technology Manufacturing investment tax credit. The realization of this tax benefit remains subject to the Company’s ability to satisfy the applicable legislative and tax filing requirements.

An illustrative spot-price case scenario based on average metal prices during September 2026 returns a pre-tax NPV7% of C$438.3 million, an after-tax NPV7% of C$313.6 million, an after-tax IRR of 115.8% and payback of 0.4 years. Tables 4 and 5 and Figure 5 show fixed mine plan sensitivities. Price-only sensitivities hold the base exchange rate constant; the illustrative spot case applies USD/CAD 0.730 to revenue and US dollar milling charges, with other cost translations held at the base case rate.

The base case after-tax economic results exclude any benefit associated with the PMD tax incentive. For illustrative purposes, a separate tax sensitivity was completed assuming the Company is eligible to claim available PMD deductions on qualifying expenditures. Under this scenario, the base case after-tax NPV7% increases to C$232.1 million and the after-tax IRR increases to 99.2%. This legislation remains subject to approval.

Figure 4: Levack PEA Pre-Tax Cash Flow

Figure 4_chart

Table 4: Levack PEA Economic Summary & Sensitivity Analysis

Price Deck Unit -10% Base Case +10% Spot Price Case
Copper US$/lb $4.59 $5.10 $5.61 $6.55
Nickel US$/lb $7.20 $8.00 $8.80 $7.50
Gold US$/oz $3,240 $3,600 $3,960 $4,320
Platinum US$/oz $1,350 $1,500 $1,650 $1,785
Palladium US$/oz $1,080 $1,200 $1,320 $1,310
Silver US$/oz $40.50 $45.00 $49.50 $64.50
Cobalt US$/lb $18.00 $20.00 $22.00 $24.90
USD/CAD US$ $0.722 $0.722 $0.722 $0.730
LOM Economics          
Revenue LOM C$ million $1,405.2 $1,597.1 $1,788.9 $1,768.9
Operating cash flow C$ million $498.2 $690.0 $881.9 $864.0
Pre-tax cash flow LOM C$ million $254.1 $445.9 $637.8 $619.8
After-tax cash flow LOM C$ million $195.2 $326.9 $458.4 $446.0
Annual averages (commercial production)          
Revenue C$M/year $186.3 $211.9 $237.4 $234.5
Operating cash flow C$M/year $65.6 $91.2 $116.7 $114.1
Pre-tax cash flow C$M/year $40.6 $66.2 $91.7 $89.1
After-tax cash flow C$M/year $31.8 $49.3 $66.7 $64.9
Net Present Value & IRR          
Pre-tax NPV(7%) C$ million $174.3 $312.1 $449.9 $438.3
After-tax NPV(7%) C$ million $132.3 $227.0 $321.6 $313.6
Pre-tax IRR % 73.8% 107.7% 137.4% 136.6%
After-tax IRR % 65.1% 92.4% 116.3% 115.8%
Payback years 0.8 0.6 0.4 0.4
After-tax NPV(7%) / Initial Capex x 1.9x 3.2x 4.6x 4.5x
After-tax NPV(7%) with PMD C$ million $136.8 $232.1 $326.7 $318.6
After-tax IRR with PMD % 70.9% 99.2% 122.8% 122.3%
           

Table 5: Base case After-tax NPV(7%) Sensitivity Analysis (C$ million)

Change -20% -10% 0% 10% 20%
Copper $160.3 $193.6 $227.0 $260.3 $293.7
Nickel $139.5 $183.3 $227.0 $270.7 $314.4
Metal prices $35.9 $132.3 $227.0 $321.6 $416.1
Operating costs $315.7 $271.4 $227.0 $182.5 $138.0
Capital costs $251.2 $239.1 $227.0 $214.9 $202.8
           

Figure 5: Sensitivity Analysis

Figure 5_chart

Mining, Processing and Infrastructure

As illustrated in Figure 6, existing infrastructure at Levack includes the No. 2 production shaft from surface to the 2,900 Level, an internal No. 3 shaft connecting the 1,500 Level to the 3,600 Level, and an internal ramp from the 1,800 Level to the 5,300 Level at historic gradients of up to 18%. Historic lateral development typically used 10 ft × 10 ft track-drift profiles in waste areas and 15 ft × 16 ft profiles in ramps and access ways. The current Levack ramp standard is 15 ft × 15 ft, which is the design basis for new lateral development in the PEA mine plan.

Long-hole open stoping and cut-and-fill are the two mining methods applied in the Levack PEA, consistent with methods used historically at the operation. Long-hole open stoping is the primary method applied to the Footwall Copper, Morrison, and the majority of the Contact Nickel zones. Cut-and-fill is applied to portions of Footwall Copper zones. Appropriate mining dilution and recoveries were applied to the design stopes depending on mining method used.

The PEA mine plan is built around Levack’s existing historic level infrastructure (including the 1200, 1300, 1400, 1500, 1600, 1800, 2450, 2650, 2900 and 3600 Levels). The overall mine layout integrates the Footwall Copper zones, the Contact Nickel zones, and the Morrison Footwall Cu-PGE deposit, the shaft and decline access network, and the material-handling and haulage system into a single operating configuration. Upper zones (No.1, No.2, Main and No.7) are contemplated to be trucked directly to surface through the new decline in 45 tonne trucks. The lower zones (No.3, IOB, 1900 Zone and 20 Pillar) are contemplated to report to a new rock breaker and loading pocket at the 2,650 Level and then hoisted up the No. 2 shaft. Material from the Morrison deposit is contemplated to be trucked up existing ramps to the 2,650 Level pocket. The mine plan applies the scheduled mining recovery and dilution factors and uses paste backfill. Development waste, including 10% overbreak, is retained in the physical and cost accounting; the model does not assume all development waste is retained underground. The paste plant is existing infrastructure retained on site at Levack, with a nameplate capacity of 200 tons per hour.

Once on surface, mineralized material will be reduced to a topsize of 1.5 inches via a contractor-operated surface crusher comprised of a combination of a jaw crusher and cone crusher and then subsampled via the onsite sampling tower with representative subsamples dispatched to the sample preparation and analytical laboratory. Production lots of approximately 2,000 to 4,000 tons of mineralized material will then be shipped to third party milling facilities located in Sudbury, Ontario.

Figure 6: Levack Mine Infrastructure and Geological Zones

Figure 6 from snip

Mineral Resource Estimate

The PEA potentially mineable resources are a subset of the current Levack Mine Mineral Resource Estimate (MRE) which were updated from the initial Levack Mine MRE announced on November 18, 2025. Updated resources include additional resources within the No.7 Contact Zone and additional mineralization in the Morrison Footwall deposit. Mineral Resources are based on a CuEq cut-off grade of 2.0% CuEq for Contact Nickel zones and 2.5% CuEq for Footwall Cu-PGE zones. Indicated and Inferred Mineral Resources are summarized in Tables 6 and 7 respectively. Appropriate mining dilution and recoveries were applied to the design stopes depending on the mining method used. Jonathan Cirelli, P.Geo, Senior Geologist of Orix Geoscience Inc. is an independent Qualified Person as defined by NI 43-101 and is responsible for the current Levack Mine MRE which incorporates diamond drill data up to a cut-off of August 31, 2025.

Table 6: Indicated resource summary

Deposit Type Cut-off Grade CuEq % Short Tons Cu % Ni % Co % Pt (g/tonne) Pd (g/tonne) Au (g/tonne) Ag (g/tonne) CuEq %
Indicated
Contact 2.00 7,455,000 0.83 1.46 0.05 0.42 0.51 0.06 0.92 3.09
Footwall 2.50 343,000 7.40 1.86 0.01 2.88 5.25 1.29 29.15 12.40
Total Indicated   7,798,000 1.12 1.48 0.05 0.52 0.71 0.12 2.16 3.50
                     

Table 7: Inferred resource summary

Deposit Type Cut-off Grade CuEq % Short Tons Cu % Ni % Co % Pt (g/tonne) Pd (g/tonne) Au (g/tonne) Ag (g/tonne) CuEq %
Inferred
Contact 2.00 5,294,000 0.86 1.47 0.04 0.39 0.40 0.05 0.67 3.08
Footwall 2.50 538,000 5.28 0.78 0.01 2.53 4.78 1.36 20.56 8.78
Total Inferred   5,832,000 1.27 1.41 0.04 0.58 0.80 0.17 2.51 3.61
                     

Levack Mineral Resource Estimate Notes:

      1. The effective date of the Levack Mine Mineral Resource Estimate is August 31, 2025. This is the close out date for the final mineral resource models and mine-out models.
      2. The mineral resources are reported at a cut-off grade of 2.00 % CuEq for Contact deposits and 2.50 % CuEq for Footwall deposits.
      3. Resource CuEq is calculated using metal prices of US$4.65/lb Cu, US$7.30/lb Ni, US$14.85/lb Co, US$1,225/oz Pt, US$1,135/oz Pd, US$3,100/oz Au, and US$39/oz Ag. Metal recoveries considered are 91 % for Cu, 85 % for Ni, 68 % for Co, 64 % for Pt, 69.5 % for Pd, 70.5 % for Au, and 70 % for Ag.
      4. The mineral resource was estimated by Jonathan Cirelli, P.Geo. of Orix Geoscience Inc. and is an independent Qualified Person as defined by NI 43-101. Two recent site visits were conducted on July 9th (surface) and November 18-20th, 2025 (surface and underground).
      5. The classification of the current Mineral Resource Estimate (MRE) into Indicated and Inferred mineral resources is consistent with current 2014 CIM Definition Standards – For Mineral Resources and Mineral Reserves.
      6. All figures are rounded to reflect the relative accuracy of the estimate and numbers may not add due to rounding.
      7. The mineral resources are presented undiluted and in situ, constrained by diamond drillhole information and previous underground geological mapping, and are considered to have reasonable prospects for eventual economic extraction. The mineral resource is exclusive of mined out material. The drillhole database includes data from 10,525 surface and underground diamond drill holes completed between 1911 and 2025. The drilling totals 4,382,756 ft (1,335,864 m) including 341,394 assay intervals representing 1,393,512 ft (424,742 m) of data.
      8. Mineral resources which are not mineral reserves do not have demonstrated economic viability. An Inferred Mineral Resource has a lower level of confidence than that applying to an Indicated Mineral Resource and must not be converted to a Mineral Reserve. It is reasonably expected that most Inferred Mineral Resources could be upgraded to Indicated Mineral Resources with continued exploration.
      9. Grades for Ni, Cu, Co, Pt, Pd, Au, and Ag are estimated for each mineralization domain using ~2.0 ft (0.61 m), 2.5 ft (0.76 m), or 5.0 ft (1.52 m) composites assigned to that domain, depending on the style of mineralization. To generate grade within the blocks, the inverse distance squared (ID2) interpolation method was used for all domains. Samples were capped before compositing when required.
      10. Reliable density measurements were available for 21 % of the samples in the drillhole database (71,712 measured samples) allowing for zone-specific Ni and Cu-based regression formulas to be created and applied to estimate missing densities.
      11. The estimate of Mineral Resources may be materially affected by environmental, permitting, legal, title, taxation, socio-political, marketing, or other relevant issues.

Additional Opportunities

As the potentially mineable resources in the Levack PEA are a subset of the updated Levack MRE, the R2 Footwall Zone is not included in the PEA mining inventory, production profile, or the economic analysis as it has yet to be included in an MRE. The R2 Footwall Zone represents a new high grade, copper and precious metals-rich massive sulphide footwall vein system located approximately 600 metres northeast of the Morisson Footwall Cu-PGE deposit at Levack Mine. It was discovered via surface drilling in July 2025. Recent drilling at the R2 Footwall Zone has returned assay results up to 9.4% Cu, 2.3% Ni, 28.7 g/t Pt+Pd+Au, 52.9 g/t Ag (29.7% CuEq) over 3.4 metres in drillhole MLV-26-14A W1 (see news release dated June 22, 2026), and 9.5% Cu, 2.6% Ni, 17.5 g/t Pt+Pd+Au, and 24.9 g/t Ag (23.5% CuEq) over 2.1 metres in drillhole FNX2038-W1 (see news release dated September 17, 2026). All lengths are downhole length and true widths are highly variable and estimated to range from 30-80% of downhole length. There are currently three underground drill rigs testing the R2 Footwall Zone, including two on the new 2950 Level exploration drift which extends to within approximately 300 metres of the R2 Footwall Zone. Additional assay results will be released in due course. The R2 Footwall mineralisation may provide an opportunity for future evaluation.

Restart Decision

Based on the results of the PEA prepared in accordance with NI 43-101 Standards of Disclosure for Mineral Projects, authored by independent and experienced Qualified Persons, the Company’s Board of Directors has formally approved the plan to restart production at the Levack Mine. This work will include rehabilitating and recommissioning existing underground infrastructure and equipment, advancing the refurbishment of the production hoist and loading pocket as well as establishing underground access and exploration platforms.

The Company advises that it has not based its restart decision on a feasibility study of mineral reserves, demonstrating economic and technical viability, and, as a result, there may be an increased uncertainty of achieving any particular level of recovery of minerals or the cost of such recovery, including increased risks associated with developing a commercially mineable deposit.

Historically, such projects have a much higher risk of economic and technical failure. There is no guarantee that production will begin as anticipated or at all or that anticipated production costs will be achieved.

Failure to commence production would have a material adverse impact on the Company’s ability to generate revenue and cash flow to fund operations. Failure to achieve the anticipated production costs would have a material adverse impact on the Company’s cash flow and future profitability.

The Company further cautions that the PEA is preliminary in nature. Mineral resources, of which 2.1 million short tons considered within the PEA are classified as inferred mineral resources, are not mineral reserves and do not have demonstrated economic viability. There is no certainty that the PEA will be realized.

Technical Report Filing

The technical report in support of the above noted PEA will be filed by Magna Mining within 45 days of this news release.

Qualified Person

The PEA was prepared by AGP Mining Consultants Inc. (“AGP”), with contributions from Orix Geoscience Inc. (“Orix”), Qualitica Consulting Inc. (“Qualitica”), Libertas Metallurgy Limited (“Libertas”) and Magna Mining Inc. The scientific and technical information in this news release has been reviewed and approved by the following Qualified Persons, as defined by NI 43-101, each for the parts of the PEA for which they are responsible:

  • AGP Mining, represented by Julian Herbert, P.Eng., Senior Underground Mine Engineer, and Rodrigo Pasqua, FAusIMM, Senior Underground Mine Engineer, and Gordon Zurowski, P.Eng., Principal Mine Engineer are all independent Qualified Persons and are responsible for mining methods, the mine plan and production schedule, project infrastructure, capital and operating costs, economic analysis, environmental studies, permitting and social or community impact.
  • Jonathan Cirelli, P.Geo., Senior Geologist, Orix, an independent Qualified Person, is responsible for the geology, exploration, drilling and data verification, and the Levack Mine MRE.
  • Chantal Jolette, P.Geo., President, CEO and Principal Geologist, Qualitica, an independent Qualified Person, is responsible for sample preparation, analyses and security.
  • David Middleditch, B.Eng., MIMMM, President and Principal Metallurgist, Libertas, an independent Qualified Person, is responsible for mineral processing, metallurgical testing and recovery methods.

Mr. Cirelli conducted personal inspections of the site on July 9, 2025 (surface) and November 18–20, 2025 (surface and underground). Mr. Herbert and Mr. Zurowski conducted a personal inspection of the site on February 9, 2026.

The scientific and technical information in this press release has been reviewed and approved by David King, M.Sc., P.Geo. Mr. King is the Senior Vice President, Exploration and Geoscience for Magna Mining Inc. and is a qualified person under National Instrument 43-101.

Cautionary Statement on Forward-Looking Statements

All statements, other than statements of historical fact, contained or incorporated by reference in this press release constitute “forward-looking statements” and “forward-looking information” (collectively, “forward-looking statements”) within the meaning of applicable securities laws. Generally, these forward-looking statements can be identified by the use of forward-looking terminology, such as “may”, “might”, “potential”, “expect”, “anticipate”, “estimate”, “believe”, “could”, “should”, “would”, “will”, “continue”, “intend”, “plan”, “target”, “forecast”, “prospective”, “significant”, “robust”, “rapid” or other similar words or phrases or variations thereof. Forward-looking statements are necessarily based upon a number of assumptions that, while considered reasonable by management at the time forward-looking statements are made, are inherently subject to business, market, economic, technical and other risks, uncertainties and contingencies that may cause actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements, including risks and uncertainties relating to the failure of additional drilling and assays to support assumptions, expectations or estimates of potential mineralization, metal tonnes or grade, such as in the R2 Footwall Zone, the failure of additional drilling to support additional expansion or delineation of estimated resources, the failure to have accurately estimated declared mineral resources or mineral reserves, the failure of additional drilling to support production planning or replenish production , the failure to maintain an adequate rate of development or access to stopes to maintain production, the failure to realize expected or anticipated production rates, mine life, operating and capital costs, recoveries, processing methods, economic returns, cash flows, net present value, internal rate of return, payback period, government funding or tax incentives, commodity prices, exchange rates, future production, development and operating plans or expansions, permitting and project schedules or timelines, the lack of availability of drill rigs to implement exploration or other programs or the failure to proceed as quickly as planned with additional exploration, development, production or other drilling, continued delays for assay results, the failure to bring the Levack mine back into commercial production subsequent to the completion of the PEA because of funding or technical issues, and other risks disclosed in the Company’s most recent annual information form for the year ended December 31, 2025, available on the SEDAR+ website (at: www.sedarplus.ca). The PEA is preliminary in nature and there can be no assurance that the conclusions or estimates in the PEA that are subject to further evaluation and refinement or the economic results anticipated therein will be realized. Mineral resources that are not mineral reserves do not have demonstrated economic viability and, particularly, inferred mineral resources, on which the PEA is based, are considered too speculative geologically to have economic considerations applied to them that would enable them to be categorized as mineral reserves. Although the Company has attempted to identify important risks, uncertainties, contingencies and factors that could cause actual results to differ materially from those expressed or implied in forward-looking statements, there can be no certainty or assurance that the Company has accurately or adequately captured, accounted for or disclosed all such risks, uncertainties, contingencies or factors. Readers should place no reliance on forward-looking statements as actual results, performance or achievements may be materially different from those expressed or implied by such statements. Resource exploration and development, and mining operations, are highly speculative, characterized by several significant risks, which even a combination of careful evaluation, experience and knowledge will not eliminate. Forward-looking statements speak only as of the date they are made. The Company does not undertake to update any forward-looking statements, whether as a result of new information or future events or otherwise, except in accordance with applicable securities laws.

About Magna Mining Inc.

Magna Mining Inc. is a producing mining company with a strong portfolio of copper, nickel, and precious metals assets located in the world-class Sudbury mining district of Ontario, Canada. The Company’s McCreedy West Mine is currently in production and the adjacent Levack Mine is being restarted. These operations are supported by a pipeline of highly prospective past-producing properties including Crean Hill, Podolsky, and Shakespeare.

Magna Mining is strategically positioned to unlock long-term shareholder value through continued production, exploration upside, and near-term development opportunities across its asset base.

Additional corporate and project information is available at www.magnamining.com and through the Company’s public filings on the SEDAR+ website at www.sedarplus.ca.

For further information, please contact:

Jason Jessup
Chief Executive Officer

or

Paul Fowler, CFA
Executive Vice President
705-482-9667
Email: info@magnamining.com

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/2eb1a724-11f8-48f7-be45-5f9ea1cf73dc

https://www.globenewswire.com/NewsRoom/AttachmentNg/acbdb0e1-eaeb-4a93-ad3f-5857f20f0147

https://www.globenewswire.com/NewsRoom/AttachmentNg/d7fac647-7f5f-4c23-bd82-9fc75db9e80f

https://www.globenewswire.com/NewsRoom/AttachmentNg/80114679-bc24-4132-926d-16facb7e9aff

https://www.globenewswire.com/NewsRoom/AttachmentNg/47964b34-603c-4bc0-b27a-78471dd79862

https://www.globenewswire.com/NewsRoom/AttachmentNg/9b195a3b-83c4-42fb-b7f8-ad58a55ecad6

To Nasdaq Copenhagen

FIXING OF COUPON RATES        8 October 2026

Fixing of coupon rates effective from 12 October 2026

Effective from 12 October 2026, the coupon rates of floating-rate bonds issued by Nykredit Realkredit A/S will be adjusted.

Bonds with quarterly interest rate fixing
The new coupon rates will apply from 12 October 2026 to 11 January 2027:

Uncapped bonds
DK0030395603, (SNP), maturity in 2029, new rate as at 12 October 2026: 3.3000% pa
DK0030522149, (SNP), maturity in 2028, new rate as at 12 October 2026: 3.0000% pa

Questions may be directed to Investor Relations at investor_relations@nykredit.dk or Press Officer Peter Klaaborg, tel +45 44 55 14 94.

Attachment

VANCOUVER, British Columbia, Oct. 08, 2026 (GLOBE NEWSWIRE) — AVRICORE HEALTH INC. (TSXV: AVCR) (the “Company” or “Avricore”) is pleased to announce that its wholly owned subsidiary, HealthTab Ltd. (“HealthTab”), has completed an integration with HeartEye, a UK provider of AI-based retinal cardiovascular risk assessment. The integration creates a new referral pathway into community pharmacy: people found to be at elevated cardiovascular risk by a HeartEye retinal scan at their optician can be referred to a nearby HealthTab-enabled pharmacy for further assessment and care. HealthTab and Abbott will be showcasing their turnkey pharmacy-based point-of-care testing solution at The Pharmacy Show 2026, taking place October 11–12 at the NEC in Birmingham, including the new HeartEye integration as part of the connected patient journey.

Identify, Assess, Act in the Community

HeartEye’s Dr.Noon CVD test, developed by Mediwhale, uses AI to estimate cardiovascular risk from a retinal scan taken during a routine visit to a participating optician. When a patient is flagged at elevated risk, their Dr.Noon report QR code can now be scanned into HealthTab at a nearby pharmacy. The pharmacist carries out a point-of-care cholesterol test, which feeds an automatic QRISK3 calculation, with all results displayed together on the patient’s HealthTab dashboard to provide a more complete assessment of their cardiovascular risk.

With newly qualified pharmacists in England registering as independent prescribers from September 2026, the pathway has the potential to take patients from identification and assessment through to treatment, where appropriate, within the community. This directly supports all three of the NHS 10 Year Health Plan’s major shifts: from hospital to community, from analogue to digital, and from sickness to prevention.

For pharmacy partners, the pathway brings in new patients with identified clinical need, helping them grow their clinical services and opening a new route for patients into the HealthTab network.

“Screening is only valuable if it leads to action,” said Rodger Seccombe, CEO of Avricore Health. “Too often, people found to be at risk are told to book a GP appointment, and many never do. The expanding Barts Health programme has shown what is possible when pharmacies can assess risk and, where appropriate, start treatment in the same visit. This integration extends that model to people identified through their optician, and we believe it can be replicated across other community-based screening initiatives that identify patients upstream of the pharmacy.”

HealthTab™ at the Core of Scalable, Integrated PoCT

HealthTab™ provides a complete, turnkey solution underpinning national pharmacy-based PoCT networks, including best-in-class instruments, consumables, onboarding, training, and ongoing support for participating sites.

At its centre is a secure cloud-based platform that seamlessly connects point-of-care analyzers, patient results, QC data, and pharmacist workflows, creating a unified digital infrastructure for community-based testing.

This integrated approach ensures quality-assured testing, consistent data capture across locations, and real-time analytics to support public-health reporting and performance monitoring, while reducing implementation complexity for pharmacy partners.

Commitment to Quality and Accuracy

HealthTab™ is designed to meet the highest standards of analytical performance and reliability. Through its partnership with CEQAL Inc., a world-leading reference method laboratory and member of the CDC Cholesterol Reference Method Laboratory Network (CRMLN), HealthTab operates a comprehensive quality management program that mirrors the rigour of accredited clinical laboratories.

This includes centralized lot monitoring of reagents, mandated internal quality control, and regular external quality-assessment (EQA) events, ensuring that results generated across every participating pharmacy are accurate, traceable, and consistent with internationally recognized reference standards.

About Avricore Health Inc.

Avricore Health Inc. (TSXV: AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at advancing pharmacy practice and patient care. Through its flagship offering HealthTab™, a wholly owned subsidiary, the Company’s mission is to make actionable health information more accessible to everyone by creating the world’s largest network of rapid testing devices in community pharmacies.

Contact:

Avricore Health Inc.

info@avricorehealth.com
avricore.com

Cautionary Note Regarding Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation, including statements regarding: the potential for the integration to create a new referral pathway and support the growth of pharmacy partners’ clinical services; the potential for pharmacist prescribing to enable treatment within the pathway; the anticipated benefits for patients and the NHS; the planned showcase of the integration at The Pharmacy Show 2026; and the development of further referral pathways into the HealthTab™ network. Forward-looking information can generally be identified by words such as “will,” “may,” “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential,” “scheduled,” “targets,” and similar expressions.

Forward-looking information is based on the Company’s current expectations, estimates, and assumptions, including that general business and economic conditions will not change materially, that the Company will be able to execute its business strategy and growth plans, that required regulatory and third-party approvals will be obtained, and that key personnel will be retained. These statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors that may cause actual results to differ materially, including: failure to meet regulatory requirements; changes in market conditions; potential downturns in economic conditions; dependence on key partnerships; competition; and other factors described in the Company’s public filings available at www.sedarplus.ca.

Forward-looking information is provided as of the date of this news release and the Company does not undertake to update such information except in accordance with applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Company ranks No. 25 nationally in Healthiest Employers® program

DAYTONA BEACH, Fla., Oct. 08, 2026 (GLOBE NEWSWIRE) — Brown & Brown, Inc. (NYSE: BRO) today announced it has been named one of the 2026 Healthiest 100 Workplaces in America® by Healthiest Employers®, ranking No. 25 nationally.

The Healthiest 100 Workplaces in America honors organizations that demonstrate a commitment to adapting their programs to support employees across work environments and life stages, prioritizing flexibility, work-life balance, mental health resources and data-informed decision-making.

“Our teammates are our greatest strength, and the best us is a healthy us,” said Powell Brown, president and chief executive officer. “When people feel supported and are at their best, our customers feel it, our business benefits from it and our culture grows stronger because of it. This recognition belongs to our teammates, who make Brown & Brown a special place through the way they care for one another, serve our customers, and strive to get better every day.”

Brown & Brown supports teammate well-being through thoughtfully designed benefits and programs that address physical, mental and financial health—including mental health resources, financial wellness support and ongoing listening efforts that help the company respond to teammates’ evolving needs.

Each company on the list completed the 2026 Healthiest Employers application. The assessment’s categories, scoring, and benchmarking were developed with input from an independent national panel representing the academic, medical, wellness, human resources and business communities. Applications are evaluated on a 1–100 rubric-based scale across six categories using yes-or-no, multiple-choice and short-answer questions.

Organizations are evaluated across six categories:

  • Culture and Leadership Commitment
  • Foundational Components
  • Strategic Planning
  • Communications and Marketing
  • Programming and Interventions
  • Reporting and Analytics

Applicants for the national award are also evaluated through an additional Healthiest 100 Workplaces in America section, which considers essay responses and questions related to chronic conditions and workplace health. Details on scoring methodology can be found here.

About Brown & Brown, Inc.
Brown & Brown, Inc. (NYSE: BRO) is a leading insurance brokerage firm delivering comprehensive and customized insurance solutions and specialization since 1939. With a global presence spanning 700+ locations and a team of approximately 23,000 professionals, we are dedicated to delivering scalable, innovative strategies for our customers at every step of their growth journey. Learn more at BBrown.com.

About Healthiest Employers and Truven
Healthiest Employers® was founded in 2009 to recognize organizations leading the way in employee health and wellbeing. Today, the program is administered by Truven, a Merative business unit that helps employers, health plans, and life sciences organizations turn healthcare data into actionable intelligence through solutions including Springbuk, its health intelligence platform.

Learn more at www.merative.com/truven and www.healthiestemployers.com.

For more information:
Jenny Goco
Vice President of Public Relations & Communications
(386) 333-6066
Jenny.Goco@BBrown.com

BROSSARD, Quebec, Oct. 08, 2026 (GLOBE NEWSWIRE) — G Mining Ventures Corp. (“GMIN” or the “Corporation”) (TSX: GMIN, OTCQX: GMINF) is pleased to report preliminary production results for the quarter ended September 30, 2026 from its 100%-owned Tocantinzinho Gold Mine (“TZ”) in Pará State, Brazil.

TZ produced 44,960 ounces (“oz”) of gold (“Au”) in the third quarter of 2026, a 22% increase over Q2 2026. On a year-to-date basis, the Corporation has produced and sold 113,651 oz Au and 114,325 oz Au, respectively, putting the Corporation on track to achieve the midpoint of full-year production guidance of 160,000 to 190,000 oz Au.

Preliminary Third Quarter 2026 Operational Results Highlights:

  • Gold produced: 44,960 oz
  • Gold sold: 43,110 oz
  • Average plant throughput: 12,372 tpd
  • Average grade processed: 1.33 g/t Au
  • Gold recovery: 92.0%
  • Strip ratio: 2.47x

“Our third quarter operational results were solid and delivered the step-up in production we expected to support a strong second half of the year, with higher grades and improved gold recoveries driving production of 44,960 ounces for the quarter,” commented Louis-Pierre Gignac, President and Chief Executive Officer of GMIN. “TZ continues to perform very well, with mining rates averaging 74,209 tpd during the quarter, a 7% increase over Q2 2026. Throughput rates at the processing plant averaged 12,372 tpd with gold grades of 1.33 grams per tonne and gold recoveries of 92.0%, representing the strongest quarterly results year-to-date.”

“Mining activities remain closely aligned with the mine plan, enabling access to higher-grade Phase 2 mineralization and positioning the operation for a significant increase in grade and production in Q4,” continued Mr. Gignac. “Building on the strong operational performance delivered this quarter and together with the continued advancement of our exploration programs, we expect to deliver a strong finish to 2026 and carry that momentum into 2027.”

Table 1. TZ Preliminary Third Quarter 2026 Operational Results

  Q3 20261    Q3 2025   YTD 2026   
             
Mining Activities        
Ore Tonnes Mined kt 1,966   1,787   4,659  
Waste Tonnes Mined kt 4,861   3,275   14,005  
Total Tonnes Mined kt 6,827   5,062   18,664  
Strip Ratio Waste/Ore 2.47   1.83   3.01  
Processing Activities        
Total Tonnes Processed kt 1,138   1,094   3,213  
Avg. Plant Throughput tpd 12,372   11,890   11,770  
Avg. Gold Recovery % 92.0 % 92.3 % 91.5 %
Avg. Gold Grade Processed g/t Au 1.33   1.43   1.20  
Gold Produced oz 44,960   46,360   113,651  
Gold Sold oz 43,110   49,119   114,325  

1. Q3 2026 operating results are preliminary and subject to final reconciliation. Comparative Q3 2025 operating data are derived from the Corporation’s previously reported results.

Third Quarter 2026 Conference Call Details
The Corporation expects to release its third quarter 2026 financial and operating results after market close on Thursday, November 12, 2026. Senior management will host a conference call and webcast on Friday, November 13, 2026, at 9:00 a.m. (ET) to discuss the results. Participants may join using the following details:

The conference call will also be accessible through the GMIN investor relations website at: https://investors.gmin.gold/English/events-and-presentations/default.aspx

About G Mining Ventures Corp.
G Mining Ventures Corp. is a mining company engaged in the development, operation and exploration of precious metals projects. GMIN is well-positioned to grow into the next mid-tier precious metals producer by leveraging strong access to capital and proven development expertise. GMIN is currently anchored by the Tocantinzinho Mine in Brazil, supported by the Gurupi Project in Brazil and the Oko Gold Project in Guyana — all with significant exploration upside and located in mining-friendly jurisdictions. GMIN trades on the TSX under the symbol “GMIN” and its shares are quoted on the OTCQX network under the symbol “GMINF”.

Additional Information
For further information on GMIN, please visit the website at www.gmin.gold or contact:

Jean-François Lemonde 
Vice President, Investor Relations 
514.299.4926

Cautionary Statement on Forward-Looking Information 

All statements, other than statements of historical fact, contained in this press release constitute “forward-looking information” and “forward-looking statements” within the meaning of certain securities laws and are based on expectations and projections as of the date of this press release. Forward-looking statements contained in this press release include, without limitation, those related to (i) the Corporation remaining on track to achieve the midpoint of full-year production guidance; (ii) the anticipated access to higher-grade Phase 2 mineralization; (iii) production of Q4-2026 expected to lead to a strong finish to 2026; and (iv) the quoted comments of GMIN’s Chief Executive Officer, as well as the whole contents of the section entitled “About G Mining Ventures Corp.”.

Forward-looking statements are based on expectations, estimates and projections as of the time of this press release. Forward-looking statements are necessarily based upon several estimates and assumptions that, while considered reasonable by the Corporation as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Such assumptions include, without limitation, those relating to GMIN continuing to improve operational results and generate free cash flow as well as profitability, those relating to the price of gold and currency exchange rates, those outlined in feasibility and other technical studies relating to GMIN’s mining assets, and those underlying the items listed on the above section entitled “About G Mining Ventures Corp.”.

Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that, notably but without limitation, (i) TZ will continue operating and delivering production, recoveries and costs that will remain in line with expectations; (ii) GMIN will achieve the midpoint of full-year production guidance; (iii) a meaningful increase in grade and production will take place in Q4-2026; (iv) mining activities will remain closely aligned with the mine plan; (v) the higher-grade Phase 2 mineralization will be accessed in Q4-2026, or at all; (vi) Oko West will be brought into commercial production in 2028, or at all; or (vii) GMIN will use TZ and Oko West to grow into the next mid-tier precious metals producer, as future events could differ materially from what is currently anticipated by the Corporation. In addition, there can be no assurance that Brazil and/or Guyana will remain mining friendly and prospective jurisdictions.

By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management’s expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as several important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All of the forward-looking statements made in this press release are qualified by these cautionary statements and those made in the Corporation’s other filings with the securities regulators of Canada including, but not limited to, the cautionary statements made in the relevant sections of the Corporation’s (i) Annual Information Form dated March 25, 2026, for the financial year ended December 31, 2025, and (iii) Management Discussion & Analysis. The Corporation cautions that the foregoing list of factors that may affect future results is not exhaustive, and new, unforeseeable risks may arise from time to time. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.